Emerging Neurological Disorders A Path to Solutions

Dr Suzanne K Gazda

Medicine in the Post 2020 Era: What is Surging to the Top of the Iceberg

- Medicine is forever changed
- Millions if not billions are suffering, and the mounting toll continues to rise
- The brain and the nervous system are under siege
- Montalvan V et al showed 36.4% of LC patients have neurological problems
- 80% of vaccine injuries are neurological (React 19 survey 2021)
- We are facing a crisis of brain health



The Hippocampus May Have Been Hit the Hardest

- Stores and recalls memories , curiosity, learning and mood.
- New neurons are being formed here (neurogenesis)
- Spike protein, isolation and fear can cut off the frontal brain from the hippocampus by activating microglia that release proinflammatory cytokines
- Alzheimer's disease can be initiated or deteriorated in COVID-19 patients due to reduced hippocampal neurogenesis.
- Children who witnessed Hurricane Irma had distorted memory decreased HC neurogenesis (vs non-exposed children)



The functional and structural changes in the hippocampus of COVID-19 patients Nouraeinejad A Acta Neurologica Belgica 2023

How does isolation affect our brain?

Scientists looked at both human and animal (rodent) models to learn more about the effects of isolation and how it may negatively impact our brains.*



- Prefrontal cortex: guides social behaviors and decision-making
 Changes to the signaling processes were observed in study animals.
- People who identify as lonely showed reduced brain volume.
- Amygdala: part of the limbic system, it plays an important role in emotions & behavior.
 In people who express loneliness, scientists have observed smaller amygdala.
- Prior studies have shown that fewer personal relationships correlate to a reduced-size amygdala.

Hippocampus: regulates hormones including cortisol, the stress hormone, and is the primary memory center of the brain.

 Humans and animals in isolation may have a smaller hippocampus and reduced brain-derived neurotrophic factor resulting in poor learning and memory.
 Isolated animals exhibited higher levels of cortisol.

*From The Scientist, by C. Offord (July 13, 2020). "How Social Isolation Affects the Brain." + https://www.the-scientist.com/features/how-social-isolation-affects-the-brain-67701

"A Mind is a Terrible Thing to Waste"

- Spike protein from the mRNA vaccine, causes a neuropathological attack on our autobiographical memory (hippocampus)
- Rational thinking, psychological resilience, and natural human curiosity have been shown to be severely impaired
- Without curiosity, we might become stagnant, complacent, less open to new ideas and experiences
- He infers this was all designed to alter brain function and "mind control"



References on the Vulnerable hippocampus

- The functional and structural changes in the hippocampus of COVID-19 patients Nouraeinejad A Acta Neurologica Belgica 2023
- Larger gray matter volumes in neuropsychiatric long-COVID syndrome Besteher B Psychiatry Research 2022
- SARS-CoV-2 spike protein induces cognitive deficit and anxiety-like behavior in mouse via non-cell autonomous hippocampal neuronal death Oh, J et al Nature Scientific reports March 2022
- The functional and structural changes in the hippocampus of COVID-19 patients Nouraeinejad A Acta Neurologica Belgica 2023
- Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation Monje M et al Cell July 2022
- Dysregulation of brain and choroid plexus cell types in severe COVID-19. Yang AC et al Nature (2021)
- COVID-19 induces neuroinflammation and loss of hippocampal neurogenesis Klein R et al Res Squ Ocober 2021
- Neuroinflammation After COVID-19 With Persistent Depressive and Cognitive Symptoms Braga J et al JAMA Psychiatry May 2023

References on the Vulnerable Hippocampus

- Changes in Brain Activation Pattern During Working Memory Tasks in People With Post-COVID Condition and Persistent Neuropsychiatric Symptoms Chang L Neurology April 2023
- SARS-CoV-2 invades cognitive centers of the brain and induces Alzheimer's-like neuropathology Shen W et al bioRxIV Sept 2022
- Cortical Grey matter volume depletion links to neurological sequelae in post COVID-19 "long haulers" Rothstein T BMC Neurology
- Accelerated Brain Volume Loss Caused by Anti–β-Amyloid Drugs: A Systematic Review and Metaanalysis Alves F et al Neurology 2023
- Post-traumatic stress symptoms in COVID-19 survivors: a self-report and brain imaging follow-up study. Tu Y et al Mol Psychiatry 2021

References on the Vulnerable Hippocampus

- "SARS-CoV-2 Is Associated with Changes in Brain Structure in UK Biobank." Fidel Alfaro-Almagro Nature 2022
- Gray Matter Changes Following Mild COVID-19: An MR Morphometric Study in Healthy Young People Perlaki G et al JMRI August 23, 2023
- One-year trajectory of cognitive changes in older survivors of COVID-19 in Wuhan, China: a longitudinal cohort study. Liu YH et al JAMA Neurol. 2022
- Cerebral blood flow in patients recovered from mild COVID-19 Sen S J of Neuroimaging June 2023
- Susceptibility-Weighted Magnetic Resonance Imaging Highlights Brain Alterations in COVID Recovered Patients Mishra S et al medRxiv preprint Nov 2022
- Gray Matter Thickness and Subcortical Nuclear Volume in Men After SARS-CoV-2 Omicron Infection. Du Y et al JAMA Network Open 2023

References on the Vulnerable Hippocampus

- Cerebral micro-structural changes in COVID-19 patients—an MRI-based 3-month follow-up study Lu Y et al EClinicalMedicine 2020
- COVID-19 induces neuroinflammation and loss of hippocampal neurogenesis Klein R et al Res Square 2021
- COVID-19 causes neuronal degeneration and reduces neurogenesis in human hippocampus. Bayat AH 2022 Apoptosis
- Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation. Fernandez-Castaneda A et al Cell 2022
- COVID-19 induces CNS cytokine expression and loss of hippocampal neurogenesis Soung A et al Brain 2022

How Do We Treat Long COVID Neurological Injuries

- Case by Case
- Address retained spike protein, reduce inflammation and oxidative stress, enhance immune function, upregulate autophagy, address micro-clotting, mitochondrial dysfunction, mast cell stabilization and gut health
- Diet/ Intermittent fasting/Non-GMO diet
- Exercise/ movement/ strength training
- Neuroplasticity training
- Vagal nerve retraining
- Targeted supplements
- Never ever lose hope, Love and Joy



DR. EARL HENSLIN

BRAIN ON JOY

How the New Science of Happiness Can Help You Feel Good and Be Happy

Autophagy is a Promising Strategy for Treating Neurodegenerative Disease

- "If we started IF in mid-life, we would dramatically delay the onset of neurodegenerative disease and slow down aging" (Mark Mattson PhD)
- Neurons are particularly vulnerable to malfunction of autophagy which helps enhance the removal of prions like tau, amyloid, alpha synuclein, etc.
- Numerous studies suggest S1 drives senescence

Autophagy in Neurodegenerative Diseases: A Hunter for Aggregates Park H et al International J of Molecular Science 2020

Manipulation of autophagy by SARS-CoV-2 proteins. Koepke L et al Autophagy. 2021



What Causes Neuro-COVID and Post Vaccine Injury?

Multiple Mechanisms of Harm



Spikeopathy Mechanisms of Injury

- High levels of inflammation
- Alteration of the innate and adaptive immune system
- High levels of Oxidative Stress
- Damage to the BBB
- Autoimmune/molecular mimicry
- Prion's forming
- Micro-clotting / vascular/ low CBF
- Neurotoxins affecting the cholinergic system
- Mast Cell Activation
- Mitochondrial dysfunction
- Advances Senescence and Apoptosis
- Viral Reactivation
- Low Serotonin
- Gut Dysbiosis
- Damage to the Vagus nerve
- Neurons fusing



We Have Only Begun to See Long-Term Effects of Spike Protein Lingering

- IV injection of spike and then optical transparency clearing and imaging using light-sheet microscopy (all organs took up S1)
- S1 protein accumulated in the skull marrow and in the long bones, the tibia, and femur, indicating it reaches bone marrow niches
- Spike protein may linger for a long time
- It was also found in the meninges and brain cortex in a subset of individuals who recovered from COVID-19 and died due to non-COVID-related causes
- In the brains, only spike, no nucleocapsid and all were PCR negative

SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges- Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19 Rong Z bioRxIV March 2023





Meninges



Brain cortex



Spike Protein Lingers for up to 6 months Only in the Vaccinated

 A study by Brogna C et al 8-2023, found persistence of spike protein in the blood of 50% people who received mRNA COVID-19 vaccines at up to six months after vaccination

Detection of recombinant Spike protein in the blood of individuals vaccinated against SARS-CoV-2: Possible molecular mechanisms Brogna C et al Journal of Proteonmics Clinical Applications August 31 2023



Most Common Things We See Today

- Dysautonomia/POTS/Exercise Intolerance/HR variability/Post Exertional Malaise
- Fatigue
- Brain Fog and Cognitive Decline
- Numbness/Neuropathy/ Muscle pain/Spasms/ Weakness
- Movement disorders
- Weakness
- Dizziness
- Headaches
- New onset or worsening Neurodegenerative Disease and or Autoimmune disease
- "Functional Neurological Disorder"

Brain fog and Cognitive disorders

Cognitive impairment (CI) is regarded as one of the most disabling longterm consequences of LC and PVI



The prevalence of Cognitive COVID, ranges from 12% to 80% across studies

- Symptoms include deficits in attention, executive function, memory, language, and learning (Taquet M) (Miskowiak KW)
- Pronounced cognitive slowing in people with PCC (Zhao S 2024)
- More than 50% of long-COVID patients failed to improve 1.5 years after their initial diagnosis (Agergaard J)

Long-term Prognosis at 1.5 years after Infection with Wild-type strain of SARS-CoV-2 and Alpha, Delta, as well as Omicron Variants Agergaard J et al Journal of Infectious Disease October 2023

Long COVID is associated with severe cognitive slowing: a multicentre cross-sectional study Zhao L et al The Lancet Jan 2024



Brain Fog and Cognitive Impairment in Over 70% of Vaccine Injured

• 50% were no better a year post shot



React19 Research: Persistent Symptoms Survey #2 - React19

Cognitive deficits and memory impairments after COVID-19 vaccination Chaurasia, A et al Brain Behav Immun Health. 2022

Be Careful Out There

- NYT reported in 2021 that MVA and deaths began surging
- The U.S. Secretary of Transportation Pete Buttigieg announced in January 2023 it a "national crisis of traffic deaths"
- Could this be because drivers are not perceiving & processing information the way that they used to ?
- An astounding 45% of subjects had cognitive impairment 11 months post infection but were not reporting memory problems (Golderisi et al)

Cognitive impairment after recovery from COVID-19: Frequency, profile, and relationships with clinical and laboratory indices Golderisi S et al European Neuropsychopharmacology Feb 2024



Our Mental Sticky Note Is Lost

- Medical students with no cognitive complaints were studied after recovery from mild COVID-19 (avg age 20 y/o.
- Auditory working memory performance was significantly impaired in patients compared with controls
- AWM is a virtual 'workspace' in our mind & is crucial for learning, solving problems, keeping track of info until we need to use it
- Academic performance and day to day function will be affected

Preferential Impairment of Auditory Working Memory in Long COVID: An Observational Study of Undergraduate Medical Students Manna S et al Cureus Jan 2024



The eighth COVID-19 wave is here. Could catching it trigger Alzheimer's, Parkinson's or autoimmune disorders?

By Catherine Taylor

Posted Tue 21 Nov 2023 at 12:00pm, updated Tue 21 Nov 2023 at 1:28pm



Is Long COVID Related to Alzheimer's?

- Studies point to a concerning risk of Alzheimer's 6-12 months post infection (Taquet M) (Liu YH) (Wang L) (Davis H) (Xu E) (Douadad G) (Zhao S)
- Even mild covid can lead to an overall reduction in the size of the brain equivalent to 10 years of aging (UK Biobank 2022)

NEWS

Alzheimer's and Long Covid, could they be related?

by: <u>Brooklynn Norris</u>, <u>Stuart Price</u> Posted: Aug 13, 2022 / 02:23 PM CDT Updated: Aug 13, 2022 / 02:23 PM CDT PRESS RELEASE

COVID-19 Associated with Long-Term Cognitive Dysfunction, Acceleration of Alzheimer's Symptoms

Press release from Alzheimer's Association International Conference (AAIC[®]) 2021

- Cumulative data points to disturbing trends showing COVID-19 infections leading to lasting cognitive impairment and even Alzheimer's symptoms
- Alzheimer's Association International Conference (AAIC) report the presence of brain fog was proposed as a high risk of having AD



How One Crisis Worsens Another

- A recent publication, observed a substantial increase in spike protein post COVID whenever amyloid plaques are present (primate model)
- Spike proteins and the pathological proteins fuel neuroinflammation
- They found memory centers particularly vulnerable (entorhinal cortex and the hippocampus)
- "I believe we are going to see, in a few decades, an epidemic of early demented people, especially the ones that had COVID-19 several times. I also believe that older people who accumulate amyloid plaques in normal aging will shift to dementia and Alzheimer's much faster than the normal progression we often observe". Dr Danielle Beckman

PLEMENT 1, S369-S370, OCTOBER 2023

REPORT

SARS-COV2 INFECTION AND THE RISK FOR ALZHEIMER'S DISEASE IN THE AGED BRAIN

Danielle • Giovanne Diniz • Sean Ott • Koen Van Rompay • John Morrison

Open Access • DOI: https://doi.org/10.1016/j.ibneur.2023.08.698



Fiona Phillips, 62, blames her early dementia diagnosis on 11 years of 3am starts for breakfast television as the former GMTV host reveals her symptoms might be slowed by a groundbreaking drug trial

By Katie Hind Consultant Editor Showbusiness 00:03 02 Dec 2023, updated 07:21 02 Dec 2023



Biomarkers for Alzheimer's

- Ratio of AB 42 to 40 : Higher risk of AD: < 0.160 AD Detect
- **APO E genotype** 4 indicates the highest risk
- pTau-181: reference range: 0-55 years: 0.00–0.95 pg/mL and >55 years: 0.00–0.97 pg/mL
- p tau-217 (ALZPath test) as good as PET/CSF (Ashton N 2024)
- GFAP (glial fibrillary acidic protein)

Bollinger, J, et al. Validation of plasma amyloid- β 42/40 for detecting Alzheimer disease amyloid plaques. Neurology Dec 2021

Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers Mattson-Calgren N JAMA Neurology 2023

Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology Ashton N et al JAMA Neurology Jan 2024

What if You Knew Alzheimer's Was Coming for You?

Simple blood tests may soon be able to deliver alarming news about your cognitive health.

AD Biomarkers Predict future Decline

- Two blood-based serum biomarkers, Aβ42/40 ratio and phosphorylated tau181 were followed in middle aged women over 14 years.
- Higher levels of p-tau 181 were linked to accelerated cognitive decline and, lower AB 42/40 levels were associated with faster cognitive decline

Midlife blood test may predict cognitive decline, Alzheimer's in later life



December 21, 2023

Contact: Kim North Shine

Share on: 🗙 🥤 in

Blood-based biomarkers for Alzheimer's disease and cognitive function from mid- to late life Wang X et al Alzheimer's and Dementia J of Alzheimer's Disease Dec 2023

Long-Term Brain Injury Markers in COVID-19 Survivors: A Looming Shadow of Neurological Peril

- Studies reveal a disturbing pattern: elevated levels of brain injury markers tau, GFAP (Glial fibrillary acidic protein) and NfL (Neurofilament light chain) remained present in the blood of a significant portion of patients (Benedict M)
- Multiple other studies have shown the same but up to a year (Boutajangout A) (Frontera JA) (Bark L) (Sun B)

Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses Michael BD et al Nature Communications (2023)

Post-COVID cognitive deficits at one year are global and associated with elevated brain injury markers and grey matter volume reduction: national prospective study Benedict M et al Research Square 2024



Prion Involvement in Long COVID Is This Why Some Patients Are Not Getting Better? Big Pharma is Planning for a 300% Global Rise in Prion Disease

- Brain fog, confusion, cognition and memory issues, etc., may be associated with the symptomology, onset, and development of human prion disease (PrD) (Stefano et al)
- S1 drives prions (Nystrom S) (Zha0) (Larrsen et al)

Potential Prion Involvement in Long COVID-19 Neuropathology, Including Behavior Stefano G et al Cell Mol Neurobiol. 2023



Case # 1

- 48 y/o PhD who developed severe brain fog, insomnia, fatigue & GI symptoms after COVID in the spring of 2020. Her symptoms dramatically worsened after shot 1 & 2 (Dec 2020 and Jan 2021) & after shot 2 she developed erythromelagia, POTS and severe PEM. She began working with the Patterson group in 2021 but was not helped. Statin caused high LFT's.
- I saw first saw her in Spring 2022. Exam muscle loss in hands/normal EMG / Routine Lab negative. COVID spike antibodies greater than 25000, AD detect .17 Micro-clot 3.5/4 MRI Brain normal but NQ with high levels of neuroinflammation
- We instituted the FLCCC recovery protocol + The Bredesen Protocol



NeuroQuant Is the Gold Standard for MRI Brain Volume

- Values in red shading indicate that the reported value brain tissue: less than the 5th percentile for normative data of healthy individuals and
- Values in blue shading indicate that the reported value brain tissue: greater than the 95th percentile for normative data of healthy individuals
- Send a message <u>https://www.cortechs.ai/contact/</u> to ask for a Coretech MRI near you

Triage Brain	лаори	y nep	on			Vo	rsion 3.0
Patient ID:	Patient Nar	ne:		Sex: Age: Referring Physician:			
ENV3850671				F 47 GAZDA,	SUZANNE		
CAN INFORMATION							
can Date: 2022-04-14			ccession N PLA9918876	umber:			
ORPHOMETRY RES	ILTS		LH9910070				
	2013						
	ALL DAY		Crane and a second			AND A	
Structure	Total Vo (cm		Percentile	Cortical Brain Regions		Percentiles	
	140		-	-	Left	Right	Total 49
				Frontal Lobes	49		
/hole Brain	115		82	Frontal Lobes Superior Frontal	49	49 68	49 75
ntracranial Volume Vhole Brain Torebrain Parenchyma		i	70	Frontal Lobes Superior Frontal Middle Frontal	50	68 1	
Vhole Brain orebrain Parenchyma	115: 996	Percentil	70 es	Superior Frontal Middle Frontal Inferior Frontal	50 31 59	68 1 68	75 6 62
Vhole Brain orebrain Parenchyma otal Volumes	115: 996 Left	Percentil Right	70 es Total	Superior Frontal Middle Frontal Inferior Frontal Lateral Orbitofrontal	50 31 59 80	68 1 68 79	75 6 62 81
Yhole Brain orebrain Parenchyma otal Volumes erebral White Matter	115: 996	Percentil	70 es	Superior Frontal Middle Frontal Inferior Frontal Lateral Orbitofrontal Medial Orbitofrontal	50 31 59 80 41	68 1 68 79 31	75 6 62 81 33
Vhole Brain orebrain Parenchyma otal Volumes erebral White Matter ortical Gray Matter entricles	115: 996 Left \$0	Percentil Right 74	70 es Total 84	Superior Frontal Middle Frontal Inferior Frontal Lateral Orbitofrontal Medial Orbitofrontal Paracentral	50 31 59 80	68 1 68 79	75 6 62 81
Vhole Brain orebrain Parenchyma otal Volumes erebral White Matter ortical Gray Matter entricles erebral WM	115: 996 Left 90 31	Percentil Right 74 34	70 es Total 84 32	Superior Frontal Middle Frontal Inferior Frontal Lateral Orbitofrontal Medial Orbitofrontal	50 31 59 80 41 99	88 1 68 79 31 93	75 6 62 81 33 98
Vhole Brain orebrain Parenchyma otal Volumes erebral White Matter ortical Gray Matter entricles erebral WM ypointensities*	115: 996 Left 90 31 18	Percentil Right 74 34 14	70 es Total 84 32 15	Superior Frontal Middle Frontal Inferior Frontal Lateral Orbitofrontal Medial Orbitofrontal Paracentral Primary Motor Parietal Lobes Primary Sensory	50 31 59 80 41 99 20 53 13	68 68 79 31 93 64 35 83	75 6 62 81 33 98 39 44 46
Vhole Brain orebrain Parenchyma otal Volumes erebral White Matter ortical Gray Matter entricles erebral WM lypointensities* ubcortical Structures	115: 996 Left 90 31 18	Percentil Right 74 34 14	70 es Total 84 32 15	Superior Frontal Middle Frontal Lateral Orbitofrontal Lateral Orbitofrontal Paracentral Primary Motor Parimary Motor Primary Sensory Medial Parietal	50 31 59 80 41 99 20 53 13 33	68 1 68 79 31 93 64 35 63 42	75 6 62 81 33 98 39 44 46 36
Vhole Brain orebrain Parenchyma otal Volumes erebral White Matter ortical Gray Matter entricles erebral WM ypointensities* ubcortical Structures erebellar White Matter	115: 996 Left 90 31 18 55	Percentil Right 74 34 14 71	70 es B4 32 15 74	Superior Frontal Middle Frontal Inferior Frontal Lateral Orbitofrontal Paracentral Primary Motor Parietal Lobes Primary Sensory Medial Parietal Superior Parietal	50 31 59 80 41 20 53 13 33 91	68 1 68 79 31 93 64 35 63 42 81	75 6 62 81 33 98 39 44 46 36 89
Vhole Brain orebrain Parenchyma otal Volumes erebral White Matter ortical Gray Matter entricles erebral WM ypointensities* ubcortical Structures erebellar White Matter erebellar Gray Matter	115: 996 Left 50 31 18 55 99 44 -	Percentil Right 74 34 14 71 99 64 54	70 es 84 32 15 74 99 55 63	Superior Frontal Middle Frontal Inferior Frontal Lateral Orbitofrontal Paracentral Primary Motor Parietal Lobes Primary Sensory Medial Parietal Superior Parietal Inferior Parietal	50 31 59 80 41 20 53 13 33 91 41	68 1 68 75 31 93 64 35 81 42 81 2	75 6 62 81 33 98 39 44 46 36 89 8 8
Vhole Brain orebrain Parenchyma otal Volumes erebral White Matter ortical Gray Matter entricles erebral WM spointensities* ubcortical Structures erebellar White Matter erebellar Gray Matter rainstem halamus	115: 996 50 31 18 55 99 44 - 59	Percentil Right 74 34 14 71 71 99 64	70 es 84 32 15 74 99 55 63 99	Superior Frontal Middle Frontal Lateral Orbitofrontal Lateral Orbitofrontal Paracentral Primary Motor Parietal Lobes Primary Sensory Medial Parietal Superior Parietal Inferior Parietal Supramarginal	50 31 59 80 41 99 20 53 13 33 91 41 76	68 1 68 75 31 93 64 35 63 42 81 2 31	75 6 62 81 33 98 39 44 46 36 89 8 8 8 57
Vhole Brain orebrain Parenchyma otal Volumes erebral White Matter ortical Gray Matter entricles erebral WM ypointensities* ubcortical Structures erebellar White Matter erebellar Gray Matter rainstem halamus entral Diencephalon	115: 996 Left 50 31 18 55 99 44 -	Percentil Right 74 34 14 71 99 64 54	70 es 84 32 15 74 99 55 63	Superior Frontal Middle Frontal Inferior Frontal Lateral Orbitofrontal Paracentral Primary Motor Parietal Lobes Primary Sensory Medial Parietal Superior Parietal Inferior Parietal	50 31 59 80 41 20 53 13 33 91 41	68 1 68 75 31 93 64 35 81 42 81 2	75 6 62 81 33 98 39 44 46 36 89 8 8
Vhole Brain orebrain Parenchyma otal Volumes erebral White Matter ortical Gray Matter entricles erebral WM bucortical Structures erebellar Gray Matter reinstem halamus entral Diencephalon asal Ganglia	115: 996 Left 90 31 18 55 99 44 - 99 50 50	Percential Right 74 34 14 71 99 64 - 99 81 91	70 es 84 32 15 74 99 55 63 99 92	Superior Frontal Middle Frontal Inferior Frontal Lateral Orbitofrontal Paracentral Primary Motor Parietal Lobes Primary Sensory Medial Parietal Superior Parietal Inferior Parietal Supramarginal Occipital Lobes	50 31 59 80 41 99 20 53 13 33 91 41 76 51	88 1 68 79 31 93 64 35 83 42 81 2 31 27	75 6 62 81 33 98 39 44 46 36 89 8 8 8 57 37
Vhole Brain orebrain Parenchyma otal Volumes erebral White Matter ortical Gray Matter entricles erebral WM ypointensities* ubcortical Structures erebellar Gray Matter rebellar Gray Matter rehellar Gray Matter reinistem halamus entral Diencephalon asal Ganglia utamen	115: 996 Left 50 31 18 55 99 44 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99	Percential Right 74 34 14 71 71 99 54 - - 99 54 - - 99 91 91 99	70 es Total 84 32 15 74 99 55 63 99 92 92 99	Superior Frontal Middle Frontal Inferior Frontal Lateral Orbitofrontal Paracentral Primary Motor Parietal Lobes Primary Sensory Medial Parietal Superior Parietal Superior Parietal Supramarginal Occipital Lobes Medial Occipital Lateral Occipital Lateral Occipital Temporal Lobes	50 31 59 80 41 99 20 53 13 33 91 41 76 51 83	68 1 68 75 31 93 64 35 61 2 31 2/ 74	75 6 62 81 33 98 39 44 46 36 39 89 8 8 57 37 80
Vhole Brain orebrain Parenchyma otal Volumes erebral White Matter ortical Gray Matter entricles erebral WM ypointensities* ubcortical Structures erebellar Gray Matter reinstem halamus entral Diencephalon asal Ganglia utamen audate	1152 996 201 31 18 55 99 44 - 59 99 44 - 59 50 5	Percential Right 74 34 14 71 71 99 89 84 - - 99 81 99 81 99 6	70 es Total 84 32 15 74 99 55 63 99 99 92 99 99 55	Superior Frontal Middle Frontal Lateral Orbitofrontal Lateral Orbitofrontal Paracentral Primary Motor Parital Lobes Primary Sensory Medial Parietal Superior Parietal Superior Parietal Supramarginal Occipital Lobes Medial Occipital Lateral Occipital Temporal Lobes	50 31 59 80 41 99 20 53 13 33 91 41 76 51 83 27	88 1 68 79 31 93 64 35 83 42 81 2 31 2/ 74 9	75 6 62 81 33 98 98 98 44 46 36 89 8 8 57 37 80 13
/hole Brain orebrain Parenchyma otal Volumes erebral White Matter ortical Gray Matter entricles erebral WM ubcotical Structures erebellar White Matter erebellar Gray Matter rainstem halamus entral Diencephalon asal Ganglia utamen audate ucleus Accumbens	1152 996 Left 50 31 18 55 99 44 - - 99 90 55 13	Percential Right 74 34 14 71 71 99 54 - - 99 54 - - 99 91 91 99	70 es Total 84 32 15 74 99 55 63 99 92 92 99	Superior Frontal Middle Frontal Inferior Frontal Lateral Orbitofrontal Paracentral Primary Motor Parietal Lobes Primary Sensory Medial Parietal Superior Parietal Linferior Parietal Superior Parietal Cucipital Lobes Medial Occipital Lateral Occipital Temporal Lobes Transverse Temporal + Superior Jemporal	50 31 59 80 41 99 20 53 13 33 13 33 13 91 41 76 51 63 63 277 9 9	68 1 68 75 31 93 64 35 81 2 31 2/ 74 9 45 25	75 6 62 81 33 39 44 46 36 8 98 39 44 46 36 8 8 8 8 57 37 80 13 12 14
Anole Brain orebrain Parenchyma otal Volumes erebral White Matter ortical Gray Matter entricles erebral WM ypointensities* ubcortical Structures erebellar Gray Matter erebellar Gray Matter reinistem halamus entral Diencephalon asal Ganglia utamen audate ucleus Accumbens allidum	1152 996 201 31 18 55 99 44 - 59 99 44 - 59 50 5	Percential Right 74 34 14 71 71 99 64 - 99 64 - 99 91 91 99 6	70 es Total 84 32 15 74 99 55 63 99 99 92 99 99 55	Superior Frontal Middle Frontal Inferior Frontal Lateral Orbitofrontal Paracentral Primary Motor Parietal Lobes Primary Sensory Medial Parietal Superior Parietal Linferior Parietal Superior Parietal Cucipital Lobes Medial Occipital Lateral Occipital Temporal Lobes Transverse Temporal + Superior Jemporal	50 31 59 80 41 99 20 53 13 33 33 91 41 76 51 41 77 9 9	68 1 68 75 31 93 64 35 81 2 31 2/ 74 9 45	75 6 62 81 33 99 99 44 46 36 89 8 8 57 37 80 13 21
Anole Brain orebrain Parenchyma otal Volumes erebral White Matter ortical Gray Matter entricles erebral WM ypointensities* ubcortical Structures erebellar White Matter erebellar Gray Matter rainstem halamus entral Diencephalon asal Ganglia utamen audate ucleus Accumbens allidum ingulate	115: 996 Left 90 31 18 55 99 44 - 99 90 90 91 92 13 2	Percentil Right 74 34 14 71 71 99 54 54 59 99 51 99 6 6 50 0	70 es Total 84 32 15 74 99 55 63 99 92 92 92 92 92 26 1	Superior Frontal Middle Frontal Lateral Orbitofrontal Lateral Orbitofrontal Paracentral Primary Motor Parital Lobes Primary Sensory Medial Parietal Superior Parietal Superior Parietal Supramarginal Occipital Lobes Medial Occipital Lateral Occipital Temporal Lobes	50 31 59 80 41 99 20 53 13 33 13 33 13 91 41 76 51 63 63 277 9 9	68 1 68 75 31 93 64 35 81 2 31 2/ 74 9 45 25	75 6 62 81 33 39 44 46 36 8 98 39 44 46 36 8 8 8 8 57 37 80 13 12 14
Vhole Brain orebrain Parenchyma otal Volumes erebral White Matter ortical Gray Matter entricles erebral WM bucortical Structures erebellar White Matter erebellar Gray Matter reinstem halamus entral Diencephalon asal Ganglia utamen audate ucleus Accumbens allidum ingulate nterior Cingulate	1152 996 200 31 18 55 99 44 - 99 90 5 5 13 2 87	Percentii 74 34 14 71 99 54 - 99 51 99 51 99 6 50 50 1 82	70 es Total 84 32 15 74 99 55 63 99 92 55 63 99 92 92 55 53 63 99 92 55 53 63 99 99 92	Superior Frontal Middle Frontal Lateral Orbitofrontal Lateral Orbitofrontal Paracentral Primary Motor Parietal Lobes Primary Sensory Medial Parietal Superior Parietal Superior Parietal Superior Parietal Supramarginal Occipital Lobes Medial Occipital Lateral Occipital Transverse Temporal 4 Superior Temporal Posterior Superior Temporal Sucus	50 31 59 80 41 20 53 13 33 91 41 75 51 51 51 51 9 9 9 9	68 1 68 75 31 93 64 35 81 2 31 2/ 9 45 25 82	75 6 62 81 33 98 39 44 46 36 89 8 8 9 8 9 8 9 8 9 8 9 37 80 13 21 4 4 73
/hole Brain orebrain Parenchyma otal Volumes erebral White Matter ortical Gray Matter entricles erebral WM ypointensities* ubcotrical Structures erebellar Gray Matter erebellar Gray Matter erebellar Gray Matter arainstem halamus entral Diencephalon asal Gangia utamen audate ucleus Accumbens allidum Ingulate nterior Cingulate	1152 996 Left \$00 31 18 55 99 44 - 99 44 - 99 5 113 2 87 60	Percentil Right 74 34 14 71 99 64 - 99 61 50 99 6 50 1 2 82 82 83	70 es Total 84 32 15 74 99 55 63 99 92 92 92 55 26 1 26 1 85 50	Superior Frontal Middle Frontal Lateral Orbitofrontal Paracentral Paracentral Primary Motor Parinear Motor Medial Parietal Superior Temporal 4 Superior Temporal Inferior Temporal Inferior Temporal Fusiform	50 31 59 80 41 20 53 53 53 53 51 51 63 77 9 9 9 1 10 11 10	68 1 68 75 31 93 64 35 81 2 31 2/ 74 9 45 26 82 53 10 65	75 6 62 81 33 98 39 44 46 36 89 8 8 89 8 8 57 37 80 13 21 14 73 24
Vhole Brain orebrain Parenchyma otal Volumes erebral White Matter ortical Gray Matter entricles erebral WM ypointensities* ubcortical Structures erebellar Gray Matter reibellar Gray Matter arebellar Gray Matter arebellar Gray Matter anterbellar White Matter erebellar Gray Matter allar Gray Matter ubcous Accumbens allidum ingulate nterior Cingulate	1152 996 Left 90 31 18 55 99 44 - 99 44 - 99 50 99 5 113 2 87 69 86	Percentii Right 74 34 14 71 99 64 99 64 99 91 91 6 50 91 82 38 892	70 es Total 84 32 15 74 99 55 63 99 92 99 92 99 55 63 99 92 26 1 85 50 90	Superior Frontal Middle Frontal Lateral Orbitofrontal Lateral Orbitofrontal Paracentral Primary Motor Parietal Lobes Primary Sensory Medial Parietal Superior Parietal Superior Parietal Superior Parietal Occipital Lobes Medial Occipital Lateral Occipital Lateral Occipital Temporal Lobes Transverse Temporal + Posterior Superior Temporal Sucus Middle Temporal Enform Parahippocampal	50 31 59 80 41 99 20 53 13 33 91 41 76 51 63 27 9 9 9 1 10 11 10 59	68 1 68 75 31 93 64 355 81 2 31 2/ 74 9 45 53 10 65 65	75 6 81 33 98 39 44 46 36 89 8 8 8 9 8 8 57 37 37 37 37 37 37 37 44 13 21 14 73 21 14 73 24 8 8 9 6 34 6 34 6 34 6 34 6 34 13 35 8 37 37 37 37 37 37 37 37 37 37 37 37 37
/hole Brain orebrain Parenchyma otal Volumes erebral White Matter ortical Gray Matter entricles erebral WM ypointensities* ubcotrical Structures erebellar Gray Matter erebellar Gray Matter erebellar Gray Matter arainstem halamus entral Diencephalon asal Gangia utamen audate ucleus Accumbens allidum Ingulate nterior Cingulate	1152 996 Left 90 31 18 55 99 44 - 99 44 - 99 50 99 5 113 2 87 69 86	Percentii Right 74 34 14 71 99 64 99 64 99 91 91 6 50 91 82 38 892	70 es Total 84 32 15 74 99 55 63 99 92 99 92 99 55 63 99 92 26 1 85 50 90	Superior Frontal Middle Frontal Inferior Frontal Lateral Orbitofrontal Paracentral Primary Motor Parietal Lobes Primary Sensory Medial Parietal Superior Parietal Superior Parietal Supramarginal Occipital Lobes Medial Occipital Temporal Lobes Transverse Temporal + Superior Temporal Middle Temporal Lateral Sulcus Middle Temporal Eusiform Parahippocampal Entorhinal Cortex	50 31 59 80 41 99 20 53 20 53 33 91 41 76 51 77 9 9 9 1 10 11 10 57 27	88 1 68 75 31 93 64 35 81 42 81 2/ 74 9 45 25 82 53 10 65 65 65 19 19	75 6 81 33 98 98 98 98 98 98 98 89 89 89 87 57 37 80 13 121 14 73 24 8 34 63 20
/hole Brain orebrain Parenchyma otal Volumes erebral White Matter ortical Gray Matter entricles erebral WM ypointensities* ubcotrical Structures erebellar Gray Matter erebellar Gray Matter erebellar Gray Matter arainstem halamus entral Diencephalon asal Gangia utamen audate ucleus Accumbens allidum Ingulate nterior Cingulate	1152 996 Left 90 31 18 55 99 44 - 99 44 - 99 50 99 5 113 2 87 69 86	Percentii Right 74 34 14 71 99 64 99 64 99 91 91 6 50 91 82 38 892	70 es Total 84 32 15 74 99 55 63 99 92 99 92 99 55 63 99 92 26 1 85 50 90	Superior Frontal Middle Frontal Inferior Frontal Lateral Orbitofrontal Paracentral Primary Motor Parietal Primary Sensory Medial Parietal Superior Parietal Superior Parietal Inferior Parietal Lateral Occipital Lateral Occipital Lateral Occipital Lateral Occipital Inferior Temporal Posterior Sucus Middle Temporal Inferior Temporal Inferior Temporal Fusiform Parahippocampal Entorhinal Cortex Ifomporal Pole	50 31 50 80 41 20 53 53 53 51 51 51 51 51 9 9 9 10 10 10 59 55 55	68 1 68 75 31 93 64 35 81 2 31 2/ 31 2/ 31 2/ 31 2/ 9 45 26 82 53 10 65 65 19 64	75 6 81 33 98 39 44 45 33 89 89 8 9 8 9 8 57 37 80 13 21 14 73 21 14 73 24 8 9 4 63 20 61
Vhole Brain Orebrain Parenchyma	1152 996 Left 90 31 18 55 99 44 - 99 44 - 99 50 99 5 113 2 87 69 86	Percentii Right 74 34 14 71 99 64 99 64 99 91 91 6 50 91 82 38 892	70 es Total 84 32 15 74 99 55 63 99 92 99 92 99 55 63 99 92 26 1 85 50 90	Superior Frontal Middle Frontal Inferior Frontal Lateral Orbitofrontal Paracentral Primary Motor Parietal Lobes Primary Sensory Medial Parietal Superior Parietal Superior Parietal Supramarginal Occipital Lobes Medial Occipital Temporal Lobes Transverse Temporal + Superior Temporal Middle Temporal Lateral Sulcus Middle Temporal Eusiform Parahippocampal Entorhinal Cortex	50 31 59 80 41 99 20 53 20 53 33 91 41 76 51 77 9 9 9 1 10 11 10 57 27	88 1 68 75 31 93 64 35 81 42 81 2/ 74 9 45 25 82 53 10 65 65 65 19 19	75 6 81 33 98 39 44 45 39 44 46 39 89 8 8 8 8 7 37 80 13 21 14 73 24 8 34 34 32

What Worked

- Intermittent fasting and antiinflammatory diet, Bredesen and FLCCC protocol
- Gut healing
- **Optimizing Sleep** (Melatonin/L Theanine)
- Slow return to exercise (yoga, stretching, vibration plates) Now walks 3-4 miles and adding strength training) Stretching and low-level resistance exercises were used at first since aerobic exercise worsened PEM
- Organic green tea q day
- Mindfulness and behavioral modification, strong social support
- Vagal nerve retraining (breath work, meditation)
- Optimized hormones
- Neuroplasticity training w Brain HQ
- Optimized her hearing
- Manual lymphatic drainage
- Hope

- LDN
- IVM X first 6 months
- Montelukast 10mg at hs
- Vit D3/K2
- CDP Choline
- Fluvoxamine low dose
- Nattokinase, 81 mg ASA
- Methylene Blue troche w PBM
- Trans-reservatrol
- Omega 3
- Augmented NAC
- Neuroprotect
- Nadovim
- Acetylcarnitine 1500 mg / day
- Vit E
- Cardio Miracle
- Creavitalis[®] 4 grams/ day
- Oxytocin
- Plasmalogens
- Vielight 5 X/week

What Was Not Helpful

- Maraviroc, Statin, Tolovid, Paxlovid
- Quanfacine+NAC (caused sedation, dizziness, decreased BP) and at DC caused rise in BP and extreme nervousness "Tired and wired"
- Nicotine patch
- Ketotifen (too drowsy)

Clinical experience with the α 2A-adrenoceptor agonist, guanfacine, and N-acetylcysteine for the treatment of cognitive deficits in "Long-COVID19" Feshariki-Zeheh A et al Neuroimmunology Reports Dec 2022



The Nicotine Effect

- Farsalinos et al. (2020) examined and identified neurotoxin sequences in the S1 RBD similar to snake venom that interact with nAch receptors and block the cholinergic system
- The nAChRs are the principal structures of central and autonomic neuromodulation and very important for sleep, cognition, skeletal muscle and many other things
- Nicotine patch was helpful for many LC symptoms (Letzke M)

What is the impact of nicotine on the Post-COVID-19 syndrome - a severe impairment of acetylcholineorchestrated neuromodulation: A case series Leitzke M Research Sq 2022

Editorial: nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system: Farsalinos K et al Toxicology Report 2020

What is the impact of nicotine on the Post-COVID-19 syndrome - a severe impairment of acetylcholineorchestrated neuromodulation: A case series Leitzke M et al Research Square 2022


Nicotine

- <u>https://linktr.ee/thenicotinetest</u> Is a Great resource
- Nicotine has 30x the affinity for the nicotinic acetylcholine receptors (nAChR) than acetylcholine The continuous dose of nicotine thereby liberates/blocks S1 from the receptor
- "Herx' is not uncommon
- The Mind Study is the longest study using Nicotine for Memory finding no increased risk of cancer or addiction

http://mindstudy.org/faq

Renegade Research: The Nicotine Test : Over 6000 members on Facebook





Ways to Increase Acetylcholine

Donepezil , Rivastigmine, Galantamine, Mestinon

Vagal Nerve Stimulation (cold showers, breath work, yoga, Gupta protocol, Annie Hopper protocol)

Choline

Bacopa may block acetylcholine breakdown and increase the activity of the enzyme that produces acetylcholine

Huperzine A is described as a strong acetylcholinesterase inhibitor.

Caffeine might increase acetylcholine in the brain, especially in the "memory hub" – the hippocampus

Ginkgo extract increased acetylcholine in the brain of rats

Luteolin enhances cholinergic signaling and acetylcholine levels in brain cells

EGCG improved cholinergic signaling and protected the brain in animal studies

Curcuminoids are hypothesized to be strong inhibitors of acetylcholinesterase

Rosemary, Grape Seed Extract, Cinnamon, Propolis, Ginseng, Licorice, Sulphoraphane

https://selfhacked.com/blog/cholinergic-activity-natural-boosters/

The Bredesen Protocol Restoring Balance to the Brain by Addressing Multiple Mechanisms

- Neuropathology with AD begins years before presentation
- In their pilot study, 74% of patients with showed improvement or stabilization of cognition
- They had a 145% improvement in risk factors, and an 80% improvement in quality of life compared to the control group
- Alzheimer's is treatable and preventable

ReCODE: A Personalized, Targeted, Multi-Factorial Therapeutic Program for Reversal of Cognitive Decline Bredesen D et al Biomedicines September 2021 36

Mechanisms Contribute to Alzheimer's Disease Pathophysiology

> Fixing one has little chance for success







Verses The Pharma Approach

- Amyloid drugs have failed miserably
- Amyloid is not the problem
- The number of people living with the disease doubles every 5 years beyond age 65. This number is projected to nearly triple to 14 million people by 2060 (projections BEFORE COVID)

The costs of developing treatments for Alzheimer's disease: A retrospective exploration Cummings J et al J of Alzheimer's Association 2021

The Bredesen Seven For All

- Exercise upregulates autophagy, increases cerebral blood flow and brain-derived-neurotrophic factor (BDNF), helps to improve oxygenation, the BBB, improves sleep, reduce overall stress, optimize BMI (body mass index), & improves insulin sensitivity
- Sleep is vital for memory consolidation and optimal functioning of the glymphatic system to clear cerebral toxins, including amyloid-beta and promotes metabolic health, reduces inflammation, and up-regulates the immune system.
- **Stress** (mindfulness, meditation, breath work, Yoga, online programs)



Food Is Medicine

- Higher consumption of ultra-processed foods was associated with a higher rate of global and executive function decline after a follow-up of eight years. (Goncalvas N)
- Ultra-processed food, is called "thoughtless food" because of its potentially negative effect on our thinking abilities.
- Other studies have concluded higher flavonoid use can reduce the risk of dementia

Association Between Consumption of Ultraprocessed Foods and Cognitive Decline Goncalvas N et al JAMA Neurology Dec 2022

Long-term Dietary Flavonoid Intake and Subjective Cognitive Decline in US Men and Women. Neurology Jul 2021

Dietary flavonols and risk of Alzheimer dementia Holland T et al Neurology 2021



Intermittent Fasting

- IF becomes a lifestyle/most 12 hours (ApoE 4 need 14-16 hours)
- Fasting reduces inflammation, increases BDNF, improves insulin sensitivity, metabolic and vascular health and upregulates autophagy
- In a study, published Cell Metabolism, mice that were fed on a time-restricted schedule showed improvements in memory and reduced accumulation of amyloid proteins in the brain.

Circadian modulation by time-restricted feeding rescues brain pathology and improves memory in mouse models of Alzheimer's disease Whitiaker D et al Cell August 2023

HOW FASTING IMPACTS BRAIN HEALTH



Autophagy: The "Fountain of Youth" For Your Cells

- Trans-Resveratrol induces autophagy by inhibiting mTOR, increases cerebral blood flow, boosts BDNF, protects mitochondria, lowers inflammation and reduces glutamate. Resveratrol is associated with Aβ clearance from the AD brain and neurons. Resveratrol can deactivate the TLR-4-related pathway which was found to be activated by spike protein which caused cognitive impairment in mice (Fontes-Dontes 2023)
- Methylene Blue w/PBM: enhances autophagy, clears prions and delays senescence and markedly enhances mitochondrial function, increases levels of acetylcholine, catecholamines and boosts serotonin and norepinephrine affecting anxiety, depression and memory (10-30mg / day)

Natural Products as Modulators of the Proteostasis Machinery: Implications in Neurodegenerative Diseases Cuanolo-Contreras Int J Mol Sci. 2019 Oct



Autophagy: The "Fountain of Youth" For Your Cells

- **Ivermectin** also induces autophagy through an intracellular signaling pathway named "AKT/mTOR."/clears S1/immunomodulating
- Fluvoxamine induces autophagy/inhibits platelets/activates sigma 1 receptors with neuroprotectant properties and even promoting neurogenesis.
- **Melatonin** reduces oxidative stress, inflammation, regulates the immune system, raises BDNF and activates the autophagy pathway
- **Fisetin** has anti-oxidant, anti-inflammatory activities and is neuroprotective. In preclinical models it was shown to be effective at preventing the development and/or progression of multiple neurological disorders including Alzheimer's disease, Parkinson's disease, Huntington's disease etc.
- Quality sleep
- Meditation was shown (Epel et al) to lower serum levels of Aβ40, which implies increased autophagy in brain nerve cells and a reduced risk of dementia.
- Sauna therapy
- Photo-biomodulation



Healing the Brain

- **OMEGA 3** high brain concentration of DHA can optimize synaptic plasticity and efficiency and help maintain homeostasis in the synapses It enhances the glymphatic system /shown to help prevent AD (2000-3000mg/ day) Good for the heart and the brain
- Vit D & Sunlight (get levels 60-100) boosts immune status low linked to schizophrenia and psych problems. Low D affects astrocytes and BBB and can inhibit TLR-4 which drives microglial activation. Low Vit D is linked to brain volume loss (Terak J 2022) A recent UK Biobank study showed Low D increased risk of dementia in young (Hendriks S Dec 2023)
- **CDP Citicoline** is a naturally occurring choline source for the synthesis of acetylcholine, enhances the release of dopamine, norepinephrine and serotonin significantly reduces blood-brain barrier dysfunction, and is neuroprotective. It is an intermediate in the synthesis of phospholipids, which are essential components in the assembly and repair of cell, mitochondrial & neuronal membranes.



Healing The Brain

- Vitamin E is a proven antioxidant that protects cells from oxidative stress and interacts with cellular processes, particularly those involved in neuroprotection and the maintenance of cognitive function (400-800 IU/ day)
- Flavonoids have antioxidant/anti-inflammatory effects & also can inhibit acetylcholinesterase (AChE) and help restore acetylcholine. They can help boost NGF (nerve growth factor) and BDNF (neurotrophic factors for the brain Examples Quercetin, baicalin, EGCG) A 2020 study showed higher intake less AD
- **Curcumin** increases BDNF, reduces oxidative stress and has anticoagulant, antiplatelet and fibrinolytic properties, upregulates autophagy. Most do not cross the BBB
- Magnesium threonate blocks the NMDA receptor/ modulates glutamate and is essential for maintaining brain neural plasticity. Mg deficiency has been shown in NDG disease. It crosses the BBB better than Mg glycinate



Healing the Brain

- **Berberine:** can shear up the BBB, lowers inflammation, upregulates autophagy raises BDNF and neurotransmitters in the brain: acetylcholine, norepinephrine, and serotonin.
- Beta hydroxybutyrate blocks the activation of NLRP3 inflammasome and can shear up the BBB. It also inhibits histone deacetylase (HDAC), is an activator of G protein-coupled receptor (GPCR) & can increase NGF and BDNF
- NAC has been shown to successfully cross the BBB and raise glutathione levels in the brain —in turn reducing oxidative stress and protecting the brain from free neuronal damage.
- **B vitamins :** B12, B6, and B9 (folate) can restore the integrity of the blood-brain barrier in adults with mild cognitive impairment and elevated homocysteine. They may be protective against excitotoxicity, oxidative stress, and neuroinflammation (**B complex will work**)
- **MVI** showed significant reduction in memory loss and cognitive aging (American J of Nutrition Jan 2024)



Others / So many More

- VIT K2: is a fat-soluble vitamin with many benefits including to the heart, bone, gut and brain health. It promotes mitophagy. The brain is high in K2/ reduces oxidative damage, inflammation and protects myelin. Studies strongly suggest that it could play an important role in AD prevention and therapy. (Popescu A).
- Vitamin C has important anti-inflammatory, antioxidant, and immune-enhancing properties, including increased synthesis of type I interferons and improves gut function
- Hydroxy methyl butyrate (HMB) used by body builders was shown to reduce plaques and increases factors for neuronal growth to protect learning and memory.(mice) Dose: 400-800mg/ day Also helps prevent muscle loss
- L theanine is found in green tea and increases GABA, crosses the blood-brain barrier, and can modulate inhibitory neurotransmitters, selective serotonin, and dopamine to bring calming effects.



And More

- **GlyNac:** a study showed that older humans taking GlyNAC for 16-weeks improved defects of aging. (Kumar P)
- PQQ raises blood flow to the cerebral cortex, improves mitochondria and protects nerves from the degradation caused by neurotoxins (Zhang Q)
- **PEA** targets neuro-inflammation, MCAS, pain, depression, anxiety and supports neurogenesis and synaptic pruning. (Collzi P)
- Luteolin anti-oxidant, anti-inflammatory and inhibits mast cells, inhibits microglial IL-6 release, serves as a neuroprotectant, mimics BDNF,& inhibits endothelial inflammation
- Neuroprotek: Luteolin, Quercetin and Rutin
- **Taurine** taken earlier in life is associated with better cognitive function in the elderly/deficiency may be a driver of aging (Singh 2023)



And More 😳

- **HCQ** targets multiple pathogenic mechanisms in AD including synaptic dysfunction, neuroinflammation, Aβ & tau clearance. (Varma V 2022)
- **Metformin** promotes autophagy, has anti-inflammatory, antioxidative, and anti-apoptotic effects on the nervous system, and exerts neuroprotective effects.
- Probenecid has neuroprotective, antiepileptic, and anti-inflammatory properties, as evidenced by its effect against neurological and neurodegenerative diseases. It helps block neuroinflammation and can help transport meds across the BBB/ may stabilize the kynurene pathway to be more protective
- **Sulphoraphane** enhances detox systems, can prevent breakdown of the blood-brain barrier, reduce permeability and improve cognitive function after stroke and traumatic brain injuries



Probenecid, an Old Drug with Potential New Uses for Central Nervous System Disorders and Neuroinflammation Garcia-Rodriquez C et al Biomedicine 2023

More

- Luvox helps with inflammation, autophagy, and platelet activation. It activates Sigma 1 receptors and may be a neuroprotectant and even promoting neurogenesis (Hindmarch I) (Daniels W)
- **Memantine** binds to NMDARs and prevents the influx of calcium ions, thereby preventing the disruption of synaptic plasticity and blocks the effects of glutamate. (Li P) (Scampoli C) May help pain
- Sildenafil crosses the blood brain barrier & improves cerebral blood flow. (Sanders O)One study found a 69% reduction of AD in those that use Viagroa (Fang J)
- **Monteleukast** lowers TNF Alpha and IL 6, increases glutathione and has been reported to reduce microglia activation, increase neurogenesis, be neuroprotective and restore cognitive function (Marschallinger J 2015)



Mast Cell Stabilizers

- Luteolin is a potent antioxidant, anti-inflammatory, inhibits mast cells, inhibits microglial IL-6 release, is an neuroprotectant, mimics BDNF, inhibits endothelial inflammation, macrophage activation, alleviates neuroinflammation and in animal models reduces amyloid deposition
- **NeuroProtek**[®] is a mixture of Luteolin, Quercetin and Rutin with olive pomace oil used to maximize the effects of these flavonoids by overcoming any absorption
- **Montelukast** is a leukotriene receptor antagonist (LTRA) and has antiviral activity, lowers TNF Alpha and IL 6, MCAS, increases glutathione and has been reported to reduce microglia activation, increase neurogenesis, and restore cognitive function (Marschallinger J 2015) Black box warning
- **Ketotifen** is a MC stabilizer, inhibits MC degranulation may also prevent the direct effect of histamine on microglial activation. Crosses the BBB
- **Others** Quercetin, vitamin C, local raw honey, curcumin, bromelain, probiotics, astragalus, butterbur, PEA, LDN, Pepcid, Zyrtec



Reducing Glutamate

- Glutamate and GABA are integrally related in both form and function.
 Memantine, Topamax, Lamotrigine, Ketamine, Amantadine, Zonisamide
- Don't forget diet, lower stress, exercise, avoid MSG, aspartame

Reducing glutamate –naturally.

Recommended supplements:

Taurine	500mg, twice daily
Ginger	1 to 3 capsules of a high quality product daily
Vitamin C	500mg, twice a day.
Coenzyme Q10	once daily
L-theanine	100-200mg, once daily
PQQ	10-20mg, once daily
B6	250mg, once per day
Magnesium glycinate	250mg, twice daily
Spore-based probiotic to optimize gut health and support the microbiome	
Vitamin B6 (pyridoxine). P5P is the active coenzyme form of Vitamin	
Other supplements that increase GABA include the traditional relaxing herbs: Kava, valerian, lemon balm, chamomile, and passionflower.	

Support Your Mitochondria 🔊

- **Mg glycinate** improved mitochondrial ATP synthesis, and thus greater ATP availability
- **Melatonin** protects mitochondria by scavenging for ROS and improves mitochondrial function
- **Benfotamine** is a highly available form of thiamine which is used for mitochondrial production of ATP. It decreased cognitive decline in Alzheimer's by 43%, (Xu C 2018) Helps neuropathy too/ 300mg / day
- Acteylcarnitine can decrease the risk of free radical damage within mitochondria /X's the BBB / increases Ach
- **D Ribose** Studies have looked at D Ribose in neurodegenerative diseases such as early ALS and MS with promising results)
- NAD Levels decrease w/age. Animal studies show that nicotinamide supplementation reduces neuronal death and brain edema and attenuates BBB disruption in TBI. NAD is primary fuel for sirtuins (longevity proteins that become depleted with age) /helps integrity of BBB
- L Carnitine for muscle

- Ubiquinol or CoQ10, ATP 360, MitoQ
- **PQQ** pyrroloquinoline quinone boosts mitochondria, increase CBF and protects nerves from the degradation caused by neurotoxins. It can also reduce prions.
- **CoQnol** (Designs for Health) a unique combination of ubiquinol and trans-geranylgeraniol
- Alpha Lipoid Acid has mitochondrial, antioxidant effects, can stabilize the BBB improves glucose control and insulin sensitivity, boosts acetylcholine, and easily crosses the BBB
- Mitopure promotes mitophagy which cleans up defective mitochondria and allows the mitochondria to repair themselves and improve their performance
- Oxaloacetate (BENAGENE) is a ketone that can dramatically impact cellular energy production In a ME/CFS study : 500 mg bid to tid up to 1000 mg tid All got better (Kaufman et al)
- **Glycine** impacts mitochondria epigenome/has been found to have neuroprotective benefits in animal models (Ullah R et al)

Neuroprotective Effects of Herbs



- Ashwagandha (Indian ginseng) is one of the most prominent herbs prescribed as a brain rejuvenator for AD :inhibits acetylcholinesterase, reduces oxidative stress, regenerates neurons and synapses, reduces amyloid, reverses mitochondrial dysfunction, improves auditory–verbal working memory, executive function, processing speed, and cognition
- **Gotu Kola** has been used for centuries to enhance memory and cognitive functioning and to combat the effects of aging in the brain. It has calming properties (500 mg twice a day)
- Bacopa (take at night) improves stress, memory, and learning
- Lions Mane: Increases NGF
- Rhodiola increases neurotransmitters (DA and serotonin/ calming
- Whole coffee fruit extract (WCFE), dramatically increases BDNF
- Ginko Biloba protects against glutamate excitotoxicity/mitochondrial damage
- Scutellaria Baicalensis is an antioxidant, attenuates microglial activation & may improve neurogenesis in the hippocampus
- Huperzine A inhibits the breakdown of the neurotransmitter acetylcholine

Brain photo-biomodulation holds the potential to enhance mitochondrial function, increase CBF and reduce neuroinflammation

- Mitochondrial function declines with age within neurons and CBF decreases
- Near-infrared light (NIR) stimulates mitochondrial respiration in neurons by donating photons that are absorbed by cytochrome oxidase and this energy is converted into ATP for cellular use
- PBM creates mild oxidants (ROS), which leads to gene transcription and then to cellular repair and healing
- PBM improves endothelial dysfunction via increasing bioavailable NO
- Helps clear proteins and waste

Advances in photobiomodulation for cognitive improvement by near-infrared derived multiple strategies Pan W et al J of Translational Med 2023

Shining light on the head: Photobiomodulation for brain disorders Hamblin M BBA Cilnical 2016

"The Ultimate Guide to Red Light Therapy." Ari Whitten



Vielight: Now Being Tested in Long COVID

- The Neuro Gamma PBM device exposes the default mode network to stimulation with 810 nm NIR light pulsed at 40 Hz.
- Many studies show near-infrared PBM could positively cognition, memory consolidation and mental energy.
- The 40hz Gamma improves brain energy (ATP), boost the functioning of microglia, enhances cerebral blood flow, and plays a role in neuronal protection and regeneration

References at <u>https://www.vielight.com/devices/vielight-neuro-gamma/</u>

Distinct BOLD variability changes in the default mode and salience networks in Alzheimer's disease spectrum and associations with cognitive decline Zhang L et al Nature Scientific Reports 2020



Auragen Light and Sound Photobiomodulation

- Auragen's Gamma stimulation utilizes the optimal signaling mechanisms based on research studies with delivery of synchronized 40hz via the visual and the auditory cortex (Liu J 2022)
- Theta brain stimulation that provides deep rest and stress relief
- Use a massage pillow, lay on stomach to reach back of the brain

The anti-inflammatory effects of photobiomodulation are mediated by cytokines: Evidence from a mouse model of inflammation Shimoo S Frontiers Neuroscience 2023



https://reversalsolutions.com/pages/auragen-light-therapy

Plasmalogens: The Secret Tool?

- Plasmalogens are a special type of phospholipid found on cell membranes
- They are found in high concentrations in the brain and heart. They build as much as 20% of the brain
- Plasmalogen levels begin to decrease after age 50.
- Persons with dementia exhibit a more rapid decrease in plasmalogens – especially omega-3 plasmalogens.



Plasmalogen deficiency and neuropathology in Alzheimer's disease: Causation or coincidence? Goodenowe D et al Alzheimer's Dementia 2019

Plasmalogens and Chronic Inflammatory Diseases Bozell J et al Front. Physiol., 21 October 2021

Plasmalogens: The Secret Tool?

- Plasmalogen deficiency is associated with cognitive impairment and Alzheimer's disease and all cause mortality.
- 5-year mortality was directed correlated with plasmalogen level
- ProdromeNEURO[™] is designed to elevate omega-3 plasmalogens. (Prodome Science) \$550.00/3 months.
- Plasmalogens and Alzheimer's disease: a review Su X et al Lipids in Health and Disease 2019

Plasma metabolomic profiles associated with mortality and longevity in a prospective analysis of 13,512 individuals Wang F et al Nature Communications 2023

https://newsinnutrition.com/2023/01/autism-may-be-a-plasmalogen-deficiency-syndrome





Oxytocin: The Love Hormone Biological Metaphor for Safety

- Oxytocin is a hormone responsible for bonding behaviors and romantic attachment.
- Oxytocin receptors are spread widely though out the body and the brain/ hippocampus.
- Imbalances in the oxytocinergic system are implicated in neuropsychiatric diseases like autism spectrum disorder, clinical depression, NDG disease, some cancers and eating disorders.
- OXT promotes bone, cardiovascular, metabolic health, improves nocturnal frequency, calms MCAS, is profoundly anti-inflammatory & has anti-aging properties with telomere lengthening
- May help taste and smell

Effects of Oxytocin are Probably Modulated by the Autonomic Nervous System

- Modulation of the ANS improves cardiovascular and inflammatory response, leading to increased vascularization (Norman G) (Jakowski M)
- Peripherally administered oxytocin can stimulate the vagus nerve, and then this VNS is able to modulate neural pathways (Everett N)
- Oxytocin improves cerebral blood flow (Martins D)



Findings

Romantic love triggers oxytocin release

in the brain, causing euphoria.

The Power of Love

- OXT has important roles in the hippocampus, by modulating neuronal excitability, network oscillatory activity, synaptic plasticity, and social recognition memory (Talpo F)
- OXT effectively reverses some of the damage caused by amyloid plaques in the hippocampus in AD mouse (Selles M 2023) (Jiang G 2023)
- OXT increases gray matter in hippocampus (Riem M 2019)
- The neuromodulation by Oxytocin is due to the presence in many brain regions of G-protein coupled receptor complexes (Borroto-Escuela et al)

Safety

 FDA approves the use of oxytocin for pregnant women who have complications of childbirth, such as:

Cardiovascular-Renal Disease

Eclampsia

Preeclampsia

Premature Rupture of Membranes (PROM)

- * May be associated with prostate cancer correlation (not causation)
- Very rarely patients may have increased nightmares or anxiety. Stopping further administration resolves side effect

Oxytocin and cancer: An emerging link. Lerman B et al World J Clin Oncol. 2018

A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research McDonald E Pscyhoneuroendocrinology 2011



Oxytocin Dosing

- SL troche or CR tablet
- Start 50 IU for most and can increase to 100 IU hs
- Can go higher to 100 bid (this has been used in PTSD and POTS with no ill effect)



Now....Think of Someone or Something that You Really Love/Loved

Eventually, you will come to understand that love heals everything, and love is all there is.

Gary Zukav



Sarcopenia, Mitochondrial Damage and Amyloid in Muscles

- ACE-2 is expressed in skeletal/ cardiac muscle and plays an integral role in muscle pathology
- Appleman et al found mitochondrial damage, small atrophic fibers and focal necrosis along with amyloid deposits in muscle which worsened with exercise
- The amyloid deposits could be provoking autoantibodies
- Other studies have found this too plus capillary injury in muscle (Ashman T) (Hejbol EK) (Ramirez-Velez) and there the inability to extract O2 from the vasculature during exercise (Kahn P)
- Endothelial damage and micro-clotting don't help either

Muscle abnormalities worsen after post-exertional malaise in long COVID Appleman B et al Nature Communications Jan 2024





Is the EMG Really Normal? It is If You Don't Look

- Myopathic changes in quantitative EMG and/or increased jitter in small fiber EMG were seen in 63% of 84 patients with Long COVID neuromuscular symptoms.
- Electron microscopy showed damage of terminal nerves and motor endplate.

Myopathy as a cause of Long COVID fatigue: Evidence from quantitative and single fiber EMG and muscle histopathology Agergaard J et al Clinical Neurophysiology 2023



Measure to address PEM/muscle wasting

- Creatine can increase phosphocreatine stores in muscles which have been found to be low in LC. It can X the BBB and has been found to be helpful in various NDG diseases (Rochel H) Taking dietary creatine for three months substantially improved feelings of fatigue, and by six months, had produced improvements in body aches, breathing issues, loss of taste, headaches, and problems concentrating or "brain fog" compared to people given a placebo. Creavitalis 4 grams/day (Slankamena J)
- Serotonin significantly promoted longitudinal growth of skeletal muscle fibers in vitro. Increased branching, differentiation, and fusion of
 myoblasts into myotubes were also observed
- L Carnitine for muscle mitochondrial function and energy production and competes with the ACE 2 receptor (Bellamine A)
- L-arginine is an amino acid that helps the body build protein & stimulates nitric oxide production, improves collagen synthesis in tenocytes, improves tendon function and accelerates healing of damaged tendons.
- Argivit with 3 g of arginine associated with creatine, L-carnitine, aspartic acid, magnesium, selenium and vitamins C and E (Bologna C)
- **Magnesium** is a cofactor of different enzymatic reactions involved in anabolic and catabolic processes that affect muscular performance during exercise
- Cardio Miracle is a supplement with over 50 ingredients formulated to increase nitric oxide (NO) production
- Vitamin E twice a day, subjects experienced accelerated muscle recovery (Cannon et al, 1990)
- Selenium supplementation augments calcium release from the sarcoplasmic reticulum thus improves skeletal muscle performance
- Blood flow restrictive therapy
- Address endothelial damage and micro-clotting
- Physical activity focused on progressive resistance-based strength training/ LiveO2/EWOT
- Nutritional counseling to address protein needs
- Upregulate autophagy/ intermittent fasting with time restricted eating should not cause muscle wasting (Philips M 2024)

Evaluation for Brain Fog / MCI/ Cognitive



- Chem 12, CBC, Vit D, Vit B12, ESR , IgG and IgG subsets, ANA, TFTs, free T 3 and free T 4, thyroglobulin antibody, Hgba1C, fasting insulin, homocysteine, APOE genotype, MTHFR, heavy metals, Copper, TGF beta, VEGF, Western blot, hormone levels, EBV early antigen and viral panel, HHV6 IgG and IgM, Fibrinogen, D dimer, SARS-CoV-2 Antibody (IgG), Spike, Semi-Quantitative, SARS-CoV-2 Antibodies, IgG, Spike, GAD 65
- Biomarkers: Amyloid beta 42/40, serum tau 181
- Consider Autoimmune Dementia/Paraneoplastic panel
- MRI Brain with and without GAD and Neuroquant
- Bedside MoCA
- Neuropsychological evaluation
- Some need EEG, LP CSF, RPR, HIV and some will need further integrative workup
Is Long COVID and Spike-opathy a New Form of Autoimmune Disease

More research suggests spike protein looks eerily like the body and brain

Mallory Stanislawczyk sits with her daughter Olivia, 3, while receiving a saline infusion at her Walkersville,

Megan Kelly Regrets Getting the COVID vaccine



Rise in Autoimmune Disease

VAERS reports of "Autoimmune disorder" per 1 million doses of Influenza vaccine (2018-2020) (blue) or COVID modmRNA injectable product (2021-2023) (orange) Source: https://vaers.hhs.gov



Ribosomal Frameshifting, Glitches & Off Target Protein Garbage

- Scientists discovered that in addition to the toxic "spike protein," mRNA vaccines introduce "read errors," making vaccinated individuals produce nearly random proteins with unknown and unpredictable effects.
- They found that 25-30% of vaccinated people experience unintended immune response from this 'glitch'
- The damage comes from pseudouridine substituted for uridine
- Experts are calling this a massive "developmental and regulatory failure."

The Telegraph

One in four who had Pfizer Covid jabs experience immune response

Joe Pinkstone Wed, December 6, 2023 at 11:17 AM CST · 4 min read

↑ 🗘 4.2k



Up to 30% of people receiving mRNA vaccines suffered unintended immune responses - LEON NEAL/PA

Case # 3 Autoimmune Encephalitis

- 54y/o executive w h/o DB/mild depression who after a series of 2 Covid vaccines in 2021 and then getting COVID (mild) in Jan 2022 developed HA, accelerated cognitive impairment, depression, anxiety, tremor, PEM, POTS muscle pain, mild tremor and had to stop working in early 2023. He got 3 more shots in 2022.
- Lab 12-2022: Vit D low, Mayo AE and Paraneoplastic panel negative, Sars Cov 2 IgG spike greater than 25000, Amyloid 42/40 .17, Elevated Nfl, E3/E3,CSF MS panel negative X mild increase in TP, no cells /normal EEG, MoCA 28 Incell DX sCD40L 53000, VEGF 151 but S1 in monocytes
- MRI scattered subcortical white matter changes new from 2019
- Neuroquant: Very high diffuse neuroinflammation
- EMG: normal but SFN positive

NeuroQuant[®] TBA Triage Brain Atrophy Report

Patient Information

Patien Patient ID: PPI669 Sex: M Age: 53

Referring Physician: GAZDA, SUZANNE Brain Structure Visualization

Report Information

Scan Date: 2022-11-28 Scan Accession: 100/0490 Report Date: 2022-11-28 Software Version: 3.1.2

Site Information

Paesanos Parkway Imaging 3603 Paesanos Pkwy, Suite 110 San Antonio, Lexas /8231







Brain Structure Volumes

Brain Structure	Volume (cm ³)		Normative Percentile	
Intracranial Volume	1420		-	
Whole Brain	1209		99	
Forebrain Parenchyma	1040		98	
Brain Structure	Normative Percentiles Left Right Total			
Cerebral White Matter	61	57		59
Cortical Gray Matter	98	9/		98
Ventricle	16	3		8
Cerebral WM Hypointensities*	94	96		97
Subcortical Structures				
- Cerebellar White Matter	98	92		96
- Cerebellar Gray Matter	96	96		96
- Brainstem	-	-	-	99
- Thalamus	88	97		95
- Ventral Diencephalon	99	99		99
Basal Ganglia				
Putamen	86	95		91
Caudate	72	33		54
- Nucleus Accumbens	64	15		38
- Pallidum	83	96		92
Cingulate	85	97		96
- Anterior Cingulate	67	93		89
- Posterior Cingulate	96	98		98
- Isthmus Cingulate	60	75		67

Brain Structure	Normative Percentiles		
	Left	Right	Total
Frontal Lobe	76	83	80
- Superior Frontal	50	99	89
- Middle Frontal	79	16	48
- Inferior Frontal	61	81	73
- Lateral Orbitofrontal	47	37	41
- Medial Orbitofrontal	37	24	27
- Paracentral	96	86	94
- Primary Motor	83	86	87
Parietal Lobe	99	98	99
Primary Sensory	98	72	94
- Medial Parietal	95	97	97
- Superior Parietal	11	87	72
- Inferior Parietal	99	97	92
- Supramarginal	74	82	82
Occipital Lobe	50	36	42
- Medial Occipital	69	94	85
- Lateral Occipital	38	5	14
Temporal Lobe	99	99	99
 Transverse Lemporal + Superior Lemporal 	99	99	99
- Posterior Superior Temporal Sulcus	60	35	42
- Middle Temporal	24	95	97
- Inferior Temporal	45	56	50
Fusiform	Bő	51	72
- Parahippocampal	97	93	94
- Entorhinal Cortex	99	99	99
- Temporal Pole	83	85	88
- Amygdala	74	95	89
- Hippocampus	99	99	99

"White matter hypointensities are abnorma ally low signal intensity regions within the white matter as observed on a T1-weighted MRI scan. Color Code Key:

Plnk: A tissue is below the 5th percentile OR a ventricle that is above the 95th percentile OR WM hypointensity that is above the 50th percentile. Blue: A tissue is above the 95th percentile OR a ventricle is below the 5th

percentile

Prior scan not compatible with change analysis

💬 cortechs.oi

Treatment

- We started the Bredesen protocol & the FLCCC recovery protocol I but over time he was not improving
- He continued Lamotrigine, Xanax prn, Cymbalta, Adderall and DB meds per other doctors
- Memantine, LDN, NAC, NK, LD ASA, IVM, Vit E/ B complex/ D3/K2, Melatonin, Megaspore, BCM Curcumin, Trans-Resveratrol, Omega 3, Ashwagandha, Bacopa, Mg Threonate, ALCAR, Brain HQ, Healthy Diet/IF, Light stretching, some resistance training
- Seen in the ER NOV 2023 with psychosis , he was started on Ketamine NS by psychiatry which seemed to help
- Based on careful observation, the fact that antibody panels in AE have limited accuracy, his white matter changes on MRI, elevated CSF TP, a **Brain PET was ordered and showed findings c/w AE**
- Early Jan, DC Ashwagandha, Bacopa & IVM: added Oxytocin, Probenecid, breath work, daily meditation
- The patient dramatically improving now on above plus IVIG

Treatment of Cognitive Deficits and Behavioral Symptoms Following COVID-19-Associated Autoimmune Encephalitis With Intravenous Immunoglobulin: A Case Report and Review of the Literature Naeem S et al Cureus Dec 2023

The Laboratory Diagnosis of Autoimmune Encephalitis Lee S et al J of Epilepsy Res 2016

A possible case of autoimmune encephalitis after mRNA COVID-19 booster vaccine: a case report. Abu-Abaa M et al Cureus. 2022;

Chronic Neuroinflammation is the Downfall of the Brain

- Neuroinflammation is a key pathophysiological mechanism in Neuro-COVID (Monje M) (Talla A) (Vonderheiden A) (Braga J)
- Lingering viral fragments are damaging the vasculature, the BBB, stimulating a dysregulated immune response in the brain causing neuroinflammation, autoantibodies & in some prions

Neuroinflammation: the devil is in the details Disabato D et al J of Neurochemistry 2016

Long COVID is associated with extensive in-vivo neuroinflammation on [18F]DPA-714 PET Pre-print June 2022



Autoimmune Encephalitis: Over 50% are Autoantibody Negative

- AE Is characterized by new onset seizure, cognitive impairment, and or psychiatric symptoms
- Now cases are different and more challenging
- If MRI and CSF are negative and you strongly suspect AE , PET scan is indicated in all patients
- Workup for these patients should include MRI, Neuroquant, CSF, Mayo AE and Paraneoplastic panel, IgG and IgG subsets, Nfl, AD 42/40, serum tau 181, ESR, metabolic and conventional lab & in some eval for malignancy, EEG

Treatment of Cognitive Deficits and Behavioral Symptoms Following COVID-19-Associated Autoimmune Encephalitis With Intravenous Immunoglobulin: A Case Report and Review of the Literature Naeem S et al Cureus Dec 2023

The Laboratory Diagnosis of Autoimmune Encephalitis Lee S et al J of Epilepsy Res 2016

A Case Report: Multifocal Necrotizing Encephalitis and Myocarditis after BNT162b2 mRNA Vaccination against Covid-19. Vaccines Morz M 2022



Figure 1: PET FDG Scans

In a PET scan, colors showing decreasing order of metabolic activity are red, yellow, green, and blue. Ia shows areas of hypermetabolism, indicated by red/red-white shade for the basal ganglia (1), yellow shade for the olfactory cortex (2), and superior/middle frontal gyri (3) leading to the diagnosis of autoimmune encephalitis. Following the five-day course of IVIG, these areas (1b) showed hypometabolism (trending towards normal) as indicated by a decrease in the intensity of red shade for basal ganglia (1), green shade for olfactory cortex (2), and green-yellow shade for superior and middle frontal gyri (3).

The Many Wonders of IVIG

- Multiple papers show benefit of IVIG in Long Covid
- IVIG reduces inflammasome/cytokines driving microglial cell activation and promotes autophagy
- IVIG was beneficial in a mouse model of TBI (Willis et al March 2023)
- Inactivates auto-reactive T-cells by competing for and interrupting their interaction with antigen presenting cells
- Downregulates antibody production by B-cells, interferes with B-cell proliferation via a blockade of cell surface receptors and prevents the activation of certain subtypes of B-cell
- Affects innate immunity by interrupting the steps in the complement activation cascade and blocking Fc-receptor mediated activity
- May help sheer up the BBB and **induces autophagy**
- IVIG can be helpful in many autoimmune diseases including small fiber neuropathy



IVIG Protocol

- IVIG can trigger MCAS therefore the needs for pre-meds like H1 and H2 blockers (famotidine 20 mg twice daily or ranitidine 150 mg twice daily), and steroids . Some patients with severe mast cell activation syndrome take up to 8 doses of a histamine 1 receptor blocker on the day of infusion and for 2-3 days after
- One liter of normal saline over 1 h, warmed to body temperature for patients with severe autonomic dysregulation and/or mast cell activation syndrome as temperature change is often a trigger for mast cell activation. If needed, a second liter can be given at the end of the IVIg infusion for patients with prolonged headaches despite the above treatments. Note: should not run concomitantly with the IVIg due to the risk of precipitation of the antibody molecules
- Start slowly and increase as tolerated

0.25 g/kg weekly x 4 infusions within 28 days then

0.33 g/kg approximately every 10 days × 3 infusions within 28 days then

0.50 g/kg approximately every 14 days × 2 infusions within 28 days then

0.75 g/kg approximately every 21 days × 1-2 infusions then

1.0 -2 g/kg approximately every 28 days thereafter.

Schofield and Chemali. 2018. "How we treat autoimmune small fiber polyneuropathy with immunoglobulin therapy." European Neurology 80: 304-310.

Atypical Guillain Barre Cases Rising

- There are multiple case reports of GBS after the vaccines
- GBS is an acquired demyelinating polyneuropathy that often begins in the lower extremities and ascends over time with loss of reflexes, causing muscle weakness
- 806 VAERS reports of which "verified" 295 cases of GBS from the mRNA vaccine (Abara W 2023)
- GBS incidence went down during 2020 (Keddie S 2021)
- This patient: Tetra-paresis/B/B dysfunction Jan 2021: DG FND/sent home unable to move



Functional Neurological Disorder: A Dangerous Diagnosis A Failure of Western Medicine

 At one large US tertiary care movement disorder clinic, the number of newly referred patients who received a diagnosis of FND increased by 60.1% (Hull M et al 2021)

The onset of functional movement disorders after COVID-19: A case series Rodion S Indian Journal of Psychiatry Sept 2022

Functional Neurological Disorder After SARS-CoV-2 Vaccines: Two Case Reports and Discussion of Potential Public Health Implications Butler M et al J of Pyschiatry and Clinical Neurosciences July 2021



Nerves in the Line of Fire

- 59% of LC patients and over 70% of the vaccine injuries have neuropathy symptoms.
- Neuropathic pain, sensory disturbances, neurovascular dysregulation and autonomic dysfunction
- Need SFN BX/ EMG will be normal
- MOA: Antibody mediated damage to key receptors, molecular mimicry, MCAS and/or smoldering inflammation

Prevalence Data React 19 2021

Peripheral Neuropathy Evaluations of Patients With Prolonged Long COVID Oaklander A et al Neurology 2022

SYMPTOMS OF SMALL FIBER NEUROPATHY

Pain and Burning In The Lower and Upper Extremities "Pins and Needles" Loss Of Feeling In The Hands and Feet Feet and Hands are Tender and Sore Cramping In Feet, Ankles, Calves, and Hands Numbness Fatigue Inability To Sweat Dry Eyes Skin Discoloration **Dizziness**, Lightheadedness **Difficulty Breathing Increased Heart Rate Difficulty With Bowel and Bladder Functions**

Pussycat Doll Member Shares Vax Injury

- Jessica Sutta recently spoke out about her vaccine injury occurring in 2021 after her Moderna shot with unremitting pain, uncontrollable movements and weight loss.
- DG with Small Fiber Neuropathy
- Small fibers are every where and these presentations can be varied and atypical (Nath A) (Khokhar F) (Tandia R)
- In 50% of the patients, pain and sensory disturbances from small fiber neuropathy affect the entire body and can be very severe (McAlpine L)
- Autonomic nerve fibers are usually involved





More POTS in the COVID-19 and Vaccine Fra

- A high percentage of people with long COVID have symptoms of • autonomic dysfunction and most will have SFN
- A study in Nature, (284,592 vaccinated individuals), found a **33 percent** increase in POTS. (Kwan A)
- **55%-85%** of long COVID patients c/o post-exertional malaise, ٠ brain fog, palpitations, fatigue, and dizziness (Thaweethai T)
- The vasculature is dysregulated with SFN

Apparent risks of postural orthostatic tachycardia syndrome diagnoses after COVID-19 vaccination and SARS-Cov-2 Infection Kwan A et al Nature Cardiovascular Research December 2022

POTS Subtypes

Neuropathic POTS

Characterized by decreased sympathetic innervation, particularly in legs

- Loss of sweating in extremities
- Blood pooling
- Blue/red/purple feet when standing or warm

Hypovolemic POTS

Characterized by low blood volume, both plasma and red blood cells

- Weakness
- Decreased exercise tolerance



Hyperadrenergic POTS

Characterized by elevated plasma norepinephrine and rise in systolic blood pressure when standing

- Extreme tachycardia
- Heart palpitations
- Tremor
- Migraine headaches
- Nausea/vomiting



Dysautonomia contributes to fatigue, brain fog, autonomic and neuropathic symptoms

- Patients w ME/CFS and LC had inappropriate tachycardia at rest, with a high percentage of patients with POTS.
- Lower parasympathetic activation was associated with worse cognitive performance

Dysautonomia and small fiber neuropathy in post-COVID condition and Chronic Fatigue Syndrome Azcue N Research Square 2023



Multiple Mechanisms in POTS Post COVID

- Damage to the Vagus nerve (Woo M)
- Autoimmune/Molecular mimicry: antibodies to adrenergic and muscarinic receptors, ganglionic acetylcholine receptor, NMDA receptor and Spike protein shares molecular mimicry with GPCR's (Wallukat G)
- Low Serotonin (Wong A) (Rinker L)
- Ach Nicotinic Receptors blocked (Leitzke M)
- Small Fiber Neuropathy
- Mitochondrial dysfunction (Chen CH)
- **Downregulation of ACE2** by SARS-CoV-2 increase angiotensin II (AngII), which activate release of proinflammatory cytokines (PC) & fuel the SNS (Khazaai S)

Case 3: Dysautonomia/EDS

- 41 y/o WF previously healthy after second shot in 2021 had a sore R arm and then developed crushing body pain, intractable vomiting, choking, cold extremities, feels like has rubber gloves on, extreme fatigue, severe insomnia, urinary incontinence, R side weak, neck pain, joint pain/whole body itches, No brain fog/NO cardiac SX
- One night: found unresponsive, intubated, negative eval in hospital: DG FND /depression
- Lab : high ferritin/ spike antibodies greater than 25000/ MTHFR double mutation
- Exam: Low BP/ mild tremor / hypermobile (new) /brisk reflexes/ red/ purple discoloration of hands and feet
- MRI Brain and C spine and NQ OK/ EMG normal but Syn One skin BX showed alpha synuclein
- F/u one month later: on class 2 narcotic, progressing, no control over body, bobble head, extreme joint laxity, muscle and joint pain can not control his muscles, L side weak now, loss of proprioception, balance worse, "body has been taken over by an alien"



Syn One

- Levine et al found 7 of 22 neuropathic POTS patients had cutaneous alpha-synuclein deposition
- Miglis et al report the presence of p-syn in five young patients with Long-COVID POTS (LC-POTS) but without prodromal features of neurodegenerative disease.

Trans-synaptic spreading of alpha-synuclein pathology through sensory afferents leads to sensory nerve degeneration and neuropathic pain Ferreira N et al Acta Neuropathologica Communications 2021

Microscopic Description		
Phosphorylated Alpha-Synuclein	Intraepidermal Nerve Fibers	
Abnormal	Normal	
Phosphorylated alpha-synuclein deposition was observed in the posterior cervical biopsy.	Intraepidermal nerve fiber density was normal in all biopsies.	
Amyloid Deposition (Congo Red)	Skin Histology (Hematoxylin and Eosin)	
Normal	Normal	
Modified Congo red staining shows no evidence of apple-green birefringence under polarized light in any of the biopsies.	Routine hematoxylin and eosin staining show no histopathologic abnormalities in any of the biopsies (see page 2).	

Syncleinopathies Diagnosed with the Syn One Skin Punch Biopsy CND Life Sciences

- Parkinson's disease
- Dementia with Lewy bodies
- Multiple system atrophy
- Pure autonomic failure
- REM sleep behavior disorder
- Dysautonomia w POTS or in Long COVID

Alpha-Synuclein in Skin Nerve Fibers as a Biomarker for Alpha-Synucleinopathies. Kim JY et al J Clin Neurol. 2019 Epub 2019

The Synuclein-One Study: Skin Biopsy Detection of Phosphorylated alphasynuclein for Diagnosis of the Synucleinopathies. Presented at: AAN Annual Meeting; April 2023 Gbbions C et al





Examples of nerve fibers from two patients (A–C and D–F). On the left (A and D), nerve fibers surrounding a blood vessel are shown in green through immunostaining with protein gene product 9.5 (PGP9.5). In B and E, the presence of phosphorylated α -synuclein (P–SYN) is seen in red. In C and F, the merged image reveals the presence of intra-axonal phosphorylated α -synuclein in orange

EDS: Be Vigilant

- The outcomes of five women, ages 33 to 51, who did not have a history of a hypermobility disorder were recently reported (Logarbo B Dec 2023) and were found to have new onset EDS
- Up to 15 months after getting COVID-19, all patients developed persistent and debilitating fatigue, accompanied by cognitive dysfunction, joint pain, and dysautonomia
- All had MCAS and were homozygous for MTHFR
- EDS often have high MCAS and SFN
- Musculoskeletal complications and hypermobility are reported in Long COVID (Swarnaker R)(Hakim A) (Gavrilova M)
- This is due to misdirected immune response to connective tissue post COVID or PVI (Logarbo B)

https://www.midwesterndoctor.com/p/the-hidden-link-between-hypermobility

https://www.midwesterndoctor.com/p/how-to-improve-zeta-potential-and

What Will Her Future Hold?

 A large and long of study suggests a phenotype conversion rate of 6.25% per year, with 73.5% of the cohort developing a neurodegenerative disease, most commonly an alpha-synucleinopathy, over 12 years of follow up (Postuma RB)

Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behavior disorder: a multi-center study Postuma RB Brain 2019



Treatments initiated

- Zyrtec, Pepcid, Zafirlukast (Accolate) bid
- Quercetin one twice a day
- Luvox 25 mg once a day X one week then one twice a day
- Baby ASA /NTK
- LDN/IVM
- NAC one twice a day
- Vitamin C and manganese to help produce collagen
- Methylated B vitamins +Zinc ((Vitamins B6 and B12, zinc also play a role in the production of collagen and B for MTHFR)
- Omega 3 one twice a day
- BCM Curcumin one to two twice a day
- Sunlight every day to help increase liquid crystalline water and increase VIT D
- Divinia water (deuterium depleted water in recyclable glass bottles)
- Vegetable juicing every day (benefits of juicing is the presence of liquid crystalline water, DDW, and possibly some type of electrical charge from the plants plus nutriends)
- Kachava 2 scoops/ day one a scoop of Collagen Peptides in smoothie or other
- Physiotherapy for ligament and joint strengthening

Celine Dion announced she has SPS in 2022



28 out of 55 Human Tissues Reacted to Viral Fragments GAD was One of Them Vojdani et al Frontiers Immunology 2021

Antigens	opike protein ob	70 reactivity
SARS-CoV-2	3.40	100 ++++
Actin	0.74	17.6 +
Mitochondrial antigen	1.52	41.8 +++
(M2)		
ENA	0.85	21.0 +
NA	1.34	36.2 ++
Histone	0.65	14.8 +
S100B	0.46	9.0 +
MBP	0.53	11.1 +
NFP	1.98	56 ++++
Synapsin	0.81	19.8 +
Beta-amyloid P	0.83	20.4 +
Tau protein	0.41	7.4 +
Collagen	0.45	8.6 +
Alpha-myosin	0.72	17.0 +
Tropomyosin	0.21	1.2 -
TPO	0.98	25.1 ++
Liver microsome	1.00	25.7 ++
PDH peptide	0.91	22.9 +
GAD-65	1.35	36.5 ++
Insulin	0.25	2.5 -
Insulin-R	0.72	17.0 +
Phospholipid	0.93	23.5 +

Spike protein OD % reactivity

Antigens

Case 4 SPS

- 43y/o WF with new onset severe muscle spasms, startle phenomena, dystonic spasms, severe fatigue and brain fog, neuropsychiatric symptoms, Raynaud's, uncontrollable tremor and other bizarre movements a few weeks after vaccine # 2 in 2021
- DG FND
- MRI / all labs normal except GAD 65, Nfl high, and EMG c/w SPS
- NeuroQuant: High levels of neuroinflammation
- Not much help from initial protocol but now back working after IVIG X 6 months





GAD65-Ab Associated Neurologic Syndromes Are On A Continuous Disease Spectrum

- GAD is the rate-limiting enzyme to produce GABA (the main inhibitory neurotransmitter in the CNS)
- Anti-GAD antibodies are classically seen with SPS, cerebellar ataxia, limbic encephalitis (LE) and overlap syndromes (GAD 65 greater than 10000)
- Neurological syndromes with **low GAD 65** (atypical PKD, Myasthenia, MS, Movement disorders, Myelopathy, Immune-mediated neuropathies, Autoimmune encephalitis) (Thevarkalam M)
- GAD may be a marker of autoimmune issues but may not actually mediating disease ; it may be a marker for response to immunotherapy
- Neurofilament light chain (NfL) is a marker of axonal damage and is elevated early in the course
- IVIG is the mainstay of RX for GAD illness, and these atypical syndromes can also respond to IVIG

Early Neuroaxonal Damage in Neurologic Disorders Associated With GAD65 Antibodies Eisenhut K et al Neurology October 2023

Neurologic syndromes related to anti-GAD65 Amaia Muñoz-Lopetegi et al Neurology 2020

Neurological Manifestations of Glutamic Acid Decarboxylase Autoimmunity in Indian Patients Thevarkalam, Meena et al Annals of Indian Academy of Neurology 2023

Clinical spectrum of glutamic acid decarboxylase antibodies in a Taiwanese population. Kuo WC et al Eur J Neurol 2019

Take Home List for All

- Eat Real Food
- Intermittent Fasting
- Never go to bed without learning one new thing
- Value Sleep
- Keep your body active/ keep moving
- Immerse in Nature/ Sunshine
- Be present, be aware, be mindful



Thank you

Each and Everyday Work to Build a Better Brain



To the people still choosing their own safety, security, and emotional comfort over saving lives and protecting freedom for posterity, it's not too late to do the right thing– but someday it will be.

From Jenna McCarthy's 'Here's a Thought...'

Additional Resources

Dr Suzanne K Gazda

Improve the Immune Terrain

- LDN is immunomodulation , reduces IL-6 and TNFα & activity of toll-like receptor 4 (TLR4) Toll-like receptors recognize conserved molecular patterns and nucleic acids as part of the innate immune response
- CBD can help modulate or suppress the functioning and secretion of cytokines
- Omega 3: omega-3 and omega-6-derived metabolites have important immune-regulatory functions.
- SPM's
- Pro-resolving mediators
- Peptides like Thymosin α1 could restore the T cells by enhancing their maturation and inhibiting apoptosis In addition, it also could prevent a proinflammatory cytokine storm by increasing regulatory T cells
- HBOT increases telomere length and decreases immuno-senescence
- PLEX



• IVIG

Improve the Immune Terrain: SPM's

- Specialized pro-resolving mediators (SPMs) are endogenous small molecules produced mainly from dietary omega-3 polyunsaturated fatty acids by both structural cells and cells of the active and innate immune systems
- Pro-resolving mediators signal the immune system to stop actively responding to pro-inflammatory signals, and instead to accelerate the return to homeostasis and promote clearance of damaging byproducts, microbes, and debris by enhancing macrophage phagocytosis
- SPMs promote resolution by binding to G-protein coupled receptors that can modify cellular behaviors such as mediating pro-inflammatory chemokine, cytokine, and adipokine regulation, microRNA transcription and translocation, and cell traffic
- SPM Active 2 / day

The Resolution Code of Acute Inflammation: Novel Pro-Resolving Lipid Mediators in Resolution Serran C et al Semin Immunol. 2015 May

Ligand-specific conformational change of the G-protein–coupled receptor ALX/FPR2 determines proresolving functional responses Cooray S et al Proc Natl Acad Sci U S A. 2013
Dissolving Prions

- Quercetin disaggregates prion fibrils and decreases fibril-Induced cytotoxicity and oxidative Stress (Lee C 2020)
- Methylene blue: binding of methylene blue to a surface cleft inhibits the oligomerization and fibrillization of prion protein (Cavaliere 2018)
- Doxycycline was reported as an antiprion agent in different experimental models (Varges D 2006)
- Epigallocatechin-gallate (EGCG) interferes in different steps of amyloid formation (Fernandes L 2021)
- Most Flavonoids
- Curcumin inhibits amyloid (Ivanov F 2020)

- Intranasal Oxytocin (El-Ganainy S 2022) showed with Galantamine, reduced β-amyloid, Tau accumulation, and neuronal death/ may lengthen telomeres
- Serrapeptase and Lumbrokinase (Metkar S 2022)
- Fisetin is a natural substance found in strawberries and apples and has anti-amyloid properties (Ahmad A 2017)
- TUDAC reduces ER stress by regulating of Akt-dependent cellular prion protein (Cortez L 2015)
- HBOT reduced amyloid burden by reducing the volume of pre-existing plaques and attenuating the formation of new ones
- NanoVi produces the same biological signal your body makes to repair cell damage brought on by free radicals (eng-3)

HCQ for Alzheimer's Disease and Stolen Memories

- Using longitudinal insurance claims data from Medicare beneficiaries they found a reduced risk of AD in those on HCQ vs MTX(over 100000 patients followed)
- HCQ targets multiple pathogenic mechanisms in AD including synaptic dysfunction, neuroinflammation, Aβ clearance, and tau phosphorylation
- Rescues impaired hippocampal synaptic plasticity prior to amyloid accumulation, enhances microglial clearance of Aβ1-42, inactivates STAT3 in microglia, neurons, and astrocytes and lowers neuroinflammation

Hydroxychloroquine lowers Alzheimer's disease and related dementias risk and rescues molecular phenotypes related to Alzheimer's disease Varma V et al Molecular Psychiatry Nature Dec 2022

Metformin

- Metformin can regulate synaptic transmission & plasticity in pathological conditions but also to regulate the balance of excitation and inhibition (E/I balance) in neural networks
- Improves insulin signaling and enhances neuritic growth and has been shown to play many different roles within the brain, ranging from neuroprotective effects to positively influencing higher cognitive processes.
- Promotes autophagy in vivo and in vitro, to reduce Tau hyperphosphorylation and improve cognition
- Is a HDAC inhibitor and downregulates proinflammatory pathways
- Inhibits intracellular inflammatory pathways, activates AMPK, and increases inhibition of mTOR, which may be a major target for regulating aging
- Metformin can improve synaptic defects, memory problems and enhance cognition in animal models of AD (Pilipenko et al 2020; Saffari et al 2020).
- Metformin's ability to inhibit mTOR expression may be helping it regulate the activity of out-of-control sensory neurons that are causing so much pain in FM and other diseases.

Metformin: A Prospective Alternative for the Treatment of Chronic Pain Baeza-Flores C et al harmacol 2020

Exploring the Pharmacological Potential of Metformin for Neurodegenerative Diseases Du M et al Front. Aging Neurosci., 26 April 2022

Mast Cell Stabilization

- Montelukast (brand name Singulair) has antiviral activity, lowers TNF Alpha and IL 6 or Zafirlukast (Accolate) 20mg bid
- Supplements including luteolin, quercetin, vitamin C, local raw honey, bromelain, probiotics, astragalus, butterbur, D-HIST, PEA may reduce microglial activation
- Luteolin: calms/inhibits the mast cell response; has antiinflammatory, anti-carcinogenic, and anti-viral properties; "inhibits interleukin (IL)-6, IL-8 and VEGF
- H1 and H2 blockers
- A low histamine diet
- LDN (Low Dose Naltrexone) .5-4.5 mg per day



Address Microclotting

- Nattokinase, Streptokinase, Lumbrokinase
- Pycnogenol (protects the endothelium) 100-180mg/ day
- ASA/ Plavix / Eliquis
- **Pentoxifylline** PTX ER, 400 mg three times daily . PTX is a non-selective phosphodiesterase drug that has anti-inflammatory and antioxidant effects
- Arterosil: The endothelial glycocalyx is a microscopically thin gel-like layer that coats the entire luminal side of the vascular endothelium.
- **Curcumin** lowers fibrinogen ,Vitamin B6 exerts several effects on preventing excessive platelet aggregation & Butyrate can reduce platelet growth factor
- **Resveratrol:** A dose-dependent inhibitory effect of resveratrol on platelet aggregation has been observed in cellular and animal models.
- Vitamin C 500mg Quercetin, 500mg , Lutein 40mg all increased nitrous oxide very effectively
- Vit D may have anti-fibrotic properties
- L Arginine, Agmatine, Cardio-Miracle (all work to increase nitrous oxide). Larginine improves endothelial dysfunction by being the substrate of NO generation in endothelial cells
- SSRI like Luvox can inhibit platelet activation (sigma-1 receptor (S1R) agonist which, on the one hand, reduces the expression of IL-6, while increasing that of eNOS).
- HBOT
- Flow Therapy

Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies Xu S et al APS 2022

Nattokinase: The Heart of the Matter

- NK has potent fibrinolytic/antithrombotic activity & also has antihypertensive, anti-atherosclerotic, lipid-lowering, antiplatelet/anticoagulant, and neuroprotective actions
- NK enhanced fibrinolysis through cleavage and inactivation of PAI-1
- NK can degrade amyloid fibrils therefore the neuroprotective effect of NK are due to its proteolytic, anti-inflammatory, and antiapoptotic effects

Nattokinase: A Promising Alternative in Prevention and Treatment of Cardiovascular Diseases Chen H et al. Biomark Insights. 2018 Jul

Amyloid-Degrading Ability of Nattokinase from Bacillus subtilis Natto. Hsu eta l Journal of Agricultural and Food Chemistry, 2009



Figure 1.

Pharmacologic actions of nattokinase as related to cardiovascular health and disease.

Triple Therapy in Long COVID

- A dramatic reduction in Long COVID symptoms and microclotting was found with triple anticoagulation therapy (Pretorius R)
- The pathophysiology of Long COVID starts with damage to the endothelium (endothelialitis)
- LC symptoms are a result of a combination of microclot formation, platelet aggregates and endothelialitis a defect in oxygen transfer at a capillary level arises, leading to tissue hypoxia
- The anticoagulant regime included dual antiplatelet therapy (Clopidogrel 75mg + Aspirin 75mg) once a day, and a direct oral anticoagulant Apixaban 5mg twice a day w/ a PPI 40mg/ day

Treatment of Long COVID symptoms with triple anticoagulant therapy Pretorius R et al Research Square March 2023





Vit D and Brain Health

- Patients at Rush Memory and Aging Project had vitamin D concentrations measured in four brain regions.
- Higher brain 25(OH)D3 concentrations were associated with a 25% to 33% lower odds of dementia or mild cognitive impairment (MCI) at the last visit before death
- Low Vit D is associated with reduced gray matter
- V D deficiency affects 35 percent of adults in the United States & is among 15 adjustable lifestyle factors that appear to drive up a person's early dementia risk by 40% (UK biobank Dec 2023)

Brain vitamin D forms, cognitive decline, and neuropathology in community-dwelling older adults Shea M et al The J of Alzheimer's Dec 2022

Risk Factors for Young-Onset Dementia in the UK Biobank Hendriks S et al JAMA Neurology Dec 2023

Vitamin D supplementation and incident dementia: Effects of sex, APOE, and baseline cognitive status Ghahremani M et al Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2023



Neuroplasticity: The Brain That Changes Itself

- Time is of the essence with neuroplasticity
- Neurogenesis is the ability to create new neurons and connections between neurons throughout a lifetime
- Life should be an ongoing enrichment experience . Novelty is key
- Continued practice is essential
- Devote the time to brain recovery
- Be Patient Neurogenesis takes time

cientists have iscovered that it takes approximately 400 repetitions to create a new synapse in the brain inless it is done in play, hich case it only takes 10 to 20 repetitions.

Ways to Enhance Your Brain: Brain Games and More

- Read, learn a new language, music, meditation, social connections, gratitude practice, love and joy
- BrainHQ \$14/ month
- Luminosity \$9.95/ month
- Cogmed \$1500 for 5 weeks with a clinician
- Heart Math \$249 for the device



Treats

- Mosh bars are GF/ no added sugar/12 grams/ protein and have 7 brain nutrients and superfoods including: lion's mane, ashwagandha, omega 3's, collagen, flaxseed, vitamin B12, and D3)
- Coco-Via –3 potential benefits of cocoa flavanols are enhanced circulation, improved cognitive function and Improvements to skin (decreased wrinkles and increased skin elasticity). CocoaVia contains 500mg of cocoa flavanols per serving.

To explore the benefits of eating the right chocolate: <u>https://www.suzannegazdamd.com/blog/listen-to-your-brain-and-go-ahead-and-eat-the-chocolate</u>



Heal the Gut

- Diet
- Rhizo health
- Probiotics and for some Prebiotics
- Address MCAS
- Oral Vitamin C or HD Vit C
- Bioflavonoids
- Butyrate

	ds		Results
Diverse populations of gut bacteria Fecal matter samples mediate several beneficial effects to from 34 individuals to	were collected Parameter	Value	")- man]::
health. being vaccinated w Low Bifidobacterium levels have mRNA vaccine; nar	ith Sars-CoV-2 Total Subjects (N) hely BNT162b2 Males	34 15/34 (44.11%) 19/34 (55.88%)	
infection, inflammatory bowel 1273 (Moderna).	Age (yrs) (mean ± SEM)	55.26 ± 2.65	
obesity, and aging. Sequencing was per	ormed on fecal (mean ± SEM)	24.54 ± 0.96	
Differences in gut microbiome samples, where DNA composition can affect immunity to extracted and norma vaccination, yet the effect of mRNA downstream fabricatio	lized for library medical history (%)	4/34 (11.76%)	
vaccines, for preventing SARS-CoV- 2 infection, on the human gut microbiome is largely unknown. The numose of the study was to receiving the vaccine to	NA sequences Relative Abundance o Bilidobacterium (median, IQR) Fre-vaccination Post-vaccination	f 1.13%, 0.0016-2.52%) 0.64% (0.0015-2.48%	name Figure 1. Relative Alexandrace of various phyla before and and vaccinatios. Nethodulg press correspond to indextual subjects (v=34), and before vs. ditre vaccinations points an conversion. Blue and the biain indextual mediation vaccinations.
examine changes in <i>Bilidobacterium</i> levels in fecal samples after mRNA SARS-CoV-2 vaccination. database. The Wilcov test was used to com <i>Bilidobacterium</i> Rela over time.	pare changes in Bilidobacterium	eristics and Relative Abundance of ng Relative Abundance pre- and	values before and after valcine, respectively. * p = 0.05 valcene, re
Discussion	21 Bofer vacces	10.1	1- 1- 5
Bifidobacterium levels were significantly reduced a mRNA vaccination for SARS-CoV-2.	fter receiving		Stan

SARS-CoV-2 vaccination, the impact on human health, and if these changes occur similarly post-vaccination for other diseases.

HBOT

- Increases telomere length and decreases immunosenescence
- Induces the release of stem cells and tissue growth factors & influences genetics
- Promotes tissue regeneration, neuro-genesis, increases angiogenesis, reduces inflammation & improves mitochondrial health
- Lowers amyloid and Improves CBF (Shapira 2021) In AD most do 60 one-hour sessions over 2-3 months
- In LC: 10 sessions of HBOT to 2.4 atmospheres over 12 days. Each treatment session last 105 minutes, consisting of three 30-minute exposures to 100% oxygen, interspersed with 5-minute air brakes (Robins T 2021)



Others

- Amantadine has been shown to interfere with the SARS COV 2 docking domain and has anti-inflammatory and dopaminergic effects/weakly blocks glutamate
- **Monteleukast:** 6-week treatment of young (4 months) and old (20 months) rats with montelukast, , reduced neuroinflammation, elevated hippocampal neurogenesis and improved learning and memory in old animals. (Aigner L et al)
- Fluvoxamine improves autophagy, reduces platelet aggregation and may promote neuroplasticity (Li W 2021)
- L Carnosine might help with loss of smell for the olfactory bulb is low in this Dose is 1000 mg tid
- TUDCA exerts its effects not only by regulating and inhibiting the apoptotic cascade, but also by reducing oxidative stress, protecting the mitochondria. Being studied in ALS (1 gram bid)
- Ozone therapy seems useful in controlling inflammation, stimulating immunity, has antiviral activity and may reduce microglial cell activation



Others

- Ambroxol may mitigate protein misfolding and is being studied in ALS and Lewy Body Dementia. Research published in 2020 showed the drug also lowered levels of alpha-synuclein in Parkinson's patients and potentially improved motor symptoms. (Dose 60-300mg tid in trial)
- Aprepitant is an antagonist of NK-1R and is a selective antagonist of the NK1 receptors of neurokinins, whose main natural ligand is substance P, which is capable by itself of inducing intense emesis. It may block the storm of cytokines that maintain the state of neuro-inflammation activated by substance P. Dose: 3 consecutive days at doses of 125 mg on day 1, and 80 mg on days 2 and 3 (Renoso-Ajra 2022)
- Ubrelvy and other CGRP inhibitors : spike protein shares molecular mimicry with the CGRP receptors therefore may be stimulating these inflammatory/ pain pathways
- Agmatine attenuates the detrimental effects of activated microglia in CNS and reduces glutamate (a metabolite of L Arginine) Rescues insulin signaling in the brain

vou are not alone

AND THERE IS HOPE FOR HEALING

Others

- **Donepezil** inhibits acetylcholinesterase, produces angiogenesis and neurogenesis in the hippocampus by releasing insulin like GF 1
- **Memantine** and donepezil markedly increases BDNF levels (Meisner et al 2008) Memantine blocks the NMDA-receptor subtype of glutamate receptors preventing over-activation of glutamine receptors
- **Topiramate** increases nitric oxide and proton mediated CGRP secretion (Durham P 2006)
- Minocycline inhibits microglial activity, reduced gliosis, synaptic deficits and cognitive impairments at early pathological stages



Dr Suzanne K Gazda

- Cognitive impairments among patients in a long-COVID clinic: Prevalence, pattern and relation to illness severity, work function and quality of life Miskowiak KW et al Journal of Affective Disorders March 2023
- 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records Taquet M et al The Lancet 2021
- 6-month neurological and psychiatric outcomes in 236,379 survivors of COVID-19: a retrospective cohort study using electronic health records. Taquet M et al The Lancet Psychiatry. (2021)
- One-year trajectory of cognitive changes in older survivors of COVID-19 in Wuhan, China: a longitudinal cohort study. Liu YH et al JAMA Neurol. 2022
- Association of COVID-19 with New-Onset Alzheimer's Disease Wang L et al J of Alzheimer's July 2022
- Long COVID: major findings, mechanisms and recommendations Davis H Nat Rev Microbiol. 2023
- Long-term neurologic outcomes of COVID-19 Xu E Nature Medicine Sept 2022
- SARS-CoV-2 is associated with changes in brain structure in UK Biobank Douadad G et al Nature 2022
- Long COVID is associated with severe cognitive slowing. Zhao S et al. medRxiv 2023

- Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered Hindmarch I et al Human Psychopharmacology 2010
- Long-Term Treatment with Fluvoxamine Decreases Nonmotor Symptoms and Dopamine Depletion in a Postnatal Stress Rat Model of Parkinson's Disease Daniels W et al Oxidative Medicine and Cellular Longevity 2020
- Fluvoxamine Confers Neuroprotection via Inhibiting Infiltration of Peripheral Leukocytes and M1 Polarization of Microglia/Macrophages in a Mouse Model of Traumatic Brain Injury Shi M et al J Neurotrauma 2022
- Memantine in the Prevention of Radiation-Induced Brain Damage: A Narrative Review Scampoli C et al Cancers 2022
- Memantine ameliorates cognitive deficit in AD mice via enhancement of entorhinal–CA1 projection. Li P et al BMC Neuroscience 2021
- Memantine for the Treatment of Dementia: A Review on its Current and Future Applications Folch J et al J of Alzheimers Disease 2017

- Vitamin K2 Modulates Mitochondrial Dysfunction Induced by 6-Hydroxydopamine in SH-SY5Y Cells via Mitochondrial Quality-Control Loop Tang H et al Nutrients 2022
- Vitamin K2 Holds Promise for Alzheimer's Prevention and Treatment Popescu A et al Nutrients 2021
- Association of Vitamin K Insufficiency with Cognitive Dysfunction in Community-Dwelling Older Adults Azuma K et al Frontiers Nutrition 2021
- Vitamin K2 (Menaquinone-7) Reverses Age-Related Structural and Cognitive Deterioration in Naturally Aging Rats Elkattawy H et al Antioxidants 2021

PQQ

- Pyrroloquinoline quinone inhibits the fibrillation of amyloid proteins. Kim J et al Prion.
 2010.
- Protective effect of pyrroloquinoline quinone against Abeta-induced neurotoxicity in human neuroblastoma SH-SY5Y cells. Zhang JJ et al Neurosci Lett. 2009
- Pyrroloquinoline quinine protects rat brain cortex against acute glutamate-induced neurotoxicity. Zhang Q et al Neurochem Res. 2013
- Stimulation of nerve growth factor production by pyrroloquinoline quinone and its derivatives in vitro and in vivo. Yamaguchi Y et al Biosci Biotechnol Biochem. 1993

References NAD

- NAD+ supplementation normalizes key Alzheimer's features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency. Hou Y et al Proc. Natl. Acad. Sci.
- NAD(+) in brain aging and neurodegenerative disorders. Lautrup S et al Cell Metab. 2019;
- NAD+ in aging, metabolism, and neurodegeneration. Verdin E et al Science 2015
- Dietary niacin and the risk of incident Alzheimer's disease and of cognitive decline. Morris MC et al J. Neurol. Neurosurg. Psychiatry (2004).
- Supplementation with NAD+ and Its Precursors to Prevent Cognitive Decline across Disease Contexts Campbell J Nutrients 2022
- Nicotinamide Protects Against Axon Exitotoxity Vaur P et al The FASEB Journal 2017
- Nicotinamide riboside relieves paclitaxel-induced peripheral neuropathy and enhances suppression of tumor growth in tumor-bearing rats Hammity M et al Pain 2020
- NAD+ improves cognitive function and reduces neuroinflammation by ameliorating mitochondrial damage and decreasing ROS production in chronic cerebral hypoperfusion models through Sirt1/PGC-1α pathway. Zhao Y et al J of Neuroinflammation 2021

- Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer's disease Fang J et al Nature Aging 2022
- Sildenafil for the Treatment of Alzheimer's Disease: A Systematic Review Sanders O J of Alzheimer's Disease 2020
- Sildenafil increases muscle protein synthesis and reduces muscle fatigue Moore M et al Transl Sci 2013
- Exploring the neuroprotective effects of montelukast on brain inflammation and metabolism in a rat model of quinolinic acid-induced striatal neurotoxicity Mazzacco M et al J of inflammation 2023
- Leukotriene receptor antagonist use and cognitive decline in normal cognition, mild cognitive impairment, and Alzheimer's dementia Xiong L et al Alzheimer's Research & Therapy 2021
- The Leukotriene Receptor Antagonist Montelukast Reduces Alpha-Synuclein Load and Restores Memory in an Animal Model of Dementia with Lewy Bodies Marschallinger J et al Neurotherapeutics 2020

- Glycine and aging: Evidence and mechanisms Johnson A et al Aging Research Review 2023
- Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial Kumar P et al J of Gerontol A Biol Sci Med Sci 2023 Jan
- Glycine, the smallest amino acid, confers neuroprotection against Dgalactose-induced neurodegeneration and memory impairment by regulating c-Jun N-terminal kinase in the mouse brain Ullah R et al J of Neuroinflammation 2020
- Beneficial effects of glycine (bioglycin) on memory and attention in young and middle-aged adults. File SE et al J Clin Psychopharmacol. 1999

- Cognitive impact of COVID-19: looking beyond the short-term Miners S et al Alzheimers Res Ther. 2020
- Cerebral micro-structural changes in COVID-19 patients an MRI based 3-month follow-up study. Liu X et al EClinicalMed. 2020
- Brain fog as a Long-term Sequela of COVID-19 Nouraeinejadcor A SN Compr Clin Med. 2023
- Association of cerebrospinal fluid brain-binding autoantibodies with cognitive impairment in post-COVID-19 syndrome Franke C et al Brain Behavior and Immunity 2023
- On the reactive states of astrocytes in prion diseases Baskakov I Prion 2021
- In SARS-CoV-2, astrocytes are in it for the long- haul Huang A et al Proc Natl Acad Sci U S A. 2022 Jul
- SARS-CoV-2, long COVID, prion disease and neurodegeneration Zhao & et al Frontiers Neuroscience 2022
- Therapeutic Effects of Near Infrared Light Stimulation on Cognitive and Behaviour Symptoms of Dementia Nizamutdinov D et al FASEB Journal April 2020
- Modulating Gamma Oscillations Promotes Brain Connectivity to Improve Cognitive Impairment Liu J et al Cerebral Cortex 2022
- Near-Infrared Photobiomodulation of Living Cells, Tubulin, and Microtubules In Vitro Staelens M Front Med Tech 2022

Additional References

- Neurological manifestations of COVID-19 and other coronavirus infections: a systematic review Montalvan V et al Clin Neurol Neurosurg. 2020
- Plasma biomarkers of neurodegeneration and neuroinflammation in hospitalized COVID-19 patients with and without new neurological symptoms Boutajangout A et al Alzheimer Dementia 2021
- Characterization and Biomarker Analyses of Post-COVID-19 Complications and Neurological Manifestations Sun B et al Cells. 2021
- Central nervous system biomarkers GFAp and NfL associate with post-acute cognitive impairment and fatigue following critical COVID-19 Bark L et al Scientific Reports Nature July 2023
- Frontera JA, et al. 2022. Comparison of serum neurodegenerative biomarkers among hospitalized COVID-19 patients versus non-COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer's dementia. Alzheimers Dement.

- Association of exercise-induced autophagy upregulation and apoptosis suppression with neuroprotection against pharmacologically induced Parkinson's disease Jang Y et al J Exerc Nutrion Biochem 2018
- Obesity-Associated Neurodegeneration Pattern Mimics Alzheimer's Disease in an Observational Cohort Study Morys F et al J of Alzheimer's Disease 2023
- Is Persistent Post-COVID Headache Associated With Protein-Protein Interactions Between Antibodies Against Viral Spike Protein and CGRP Receptor?: A Case Report Oscan E et al Front Pain Res (Lausanne) 2022
- A Possible Role of Amyloidogenic Blood Clotting in the Evolving Haemodynamics of Female Migraine-With-Aura: Results From a Pilot Study De Villiers S et al Neurology Headache and Neurogenic Pain 2019
- Molecular Mimicry of SARS-CoV-2 Spike Protein in the Nervous System: A Bioinformatics Approach Cuspoca A et al Comput Struct Biotechnol J 2022
- Incident autoimmune diseases in association with a SARS-CoV-2 infection: A matched cohort study Tesch F et al preprint 2023
- High risk of autoimmune diseases after COVID-19 Sharma C et al Nature Medicine April 2023
- Autoimmune and Autoinflammatory Connective Tissue Disorders Following COVID-19 Lim S JAMA Open Network October 2023

- COVID-19 and SARS-CoV-2 Vaccines: A Cameo Role for Headache Martelliti P Int. J. Environ. Res. Public Health 2023
- <u>https://www.suzannegazdamd.com/blog---long-covid/long-haulers-syndrome-understanding-the-mechanisms-behind-resulting-headaches</u>
- <u>https://www.suzannegazdamd.com/blog---long-covid/long-haulers-syndrome-understanding-the-mechanisms-behind-resulting-headaches</u>
- Serotonin and CGRP in Migraine Aggerwal M et al Ann of Neuroscience 2012
- Is Persistent Post-COVID Headache Associated With Protein-Protein Interactions Between Antibodies Against Viral Spike Protein and CGRP Receptor?: A Case Report Oscan E et al Front Pain Res (Lausanne) 2022
- A Possible Role of Amyloidogenic Blood Clotting in the Evolving Haemodynamics of Female Migraine-With-Aura: Results From a Pilot Study De Villiers S et al Neurology Headache and Neurogenic Pain 2019

Guillain-Barre References

- Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome Keddie S Brain Feb 2021
- Reporting of acute inflammatory neuropathies with COVID-19 vaccines: subgroup disproportionality analyses in VigiBase. Vaccines Nosade R et al 2021;9:1022.
- Guillain–Barré syndrome variant occurring after SARS-CoV-2 vaccination Allen C et al Ann Neurol. 2021
- Parsonage-Turner syndrome following COVID-19 vaccination and review of the literature Chua P et al Surg Neurol Int. 2022
- Neurological complications of COVID-19: Guillain-Barre syndrome following Pfizer COVID-19 vaccine.
 Waheed S et al Cureus. 2021
- Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States Abara W et al JAMA Feb 2023
- A Case Series and Literature Review of the Association of COVID-19 Vaccination With Autoimmune Diseases: Causality or Chance? Al Allaf, et al Cureus Sept 2022

Additional References

- Anti-GAD Encephalitis Following COVID-19 Vaccination: A Case Report Deniz C et al Noro Psikiyatr Ars. 2023
- Severe Stiff-Person Syndrome After COVID The First Video-Documented COVID Exacerbation and Viral Implications Dalakus M et al Neurology March 2024
- Type 1 diabetes mellitus following SARS-CoV-2 mRNA vaccination Berna İmge Aydoğan et al Endocrine 2022
- Onset of Guillain-Barre Syndrome and Transverse Myelitis Following COVID-19 Vaccination Do K et al Cureus 2023
- MRI Features of Multiple Cranial Neuropathies in Guillain-Barré Syndrome Occurring after COVID-19 Vaccination: A Case Report Soo Y et al J Korean Soc Radiol. 2023

Stiff Person Syndrome

- Neuropsychiatric Symptoms of COVID-19 Explained by SARS-CoV-2 Proteins' Mimicry of Human Protein Interactions Yapici-Eser H et al Front Hum. Neuroscience March 2021
- Postvaccinal GABA-B receptor antibody encephalitis after ChAdOx1 nCoV-19 vaccination Ahn S et al Ann Clin Transl Neurology 2022 Oct
- Autoimmune post-COVID vaccine syndromes: does the spectrum of autoimmune/inflammatory syndrome expand? Jara L et al Clin Rheum 2022
- Severe Stiff-Person Syndrome After COVID The First Video-Documented COVID Exacerbation and Viral Implications Dalakus M et al Neurology March 2024

Small Fiber Neuropathy/POTS Refences

- Neuropathic Pain Associated with COVID-19: a Systematic Review of Case Reports Joshi D et al Curr Pain Headache Rep. 2022
- Epoch Times Atypical Small–Fiber Neuropathy Occurrence After COVID-19 Vaccination, Possibly Underdiagnosed
- Small Fiber Neuropathy After SARS-CoV-2 Infection and Vaccination: A Case-Based Comparison Schwartz B et al Cureus August 2023
- Small Fiber Neuropathy Triggered by COVID-19 Vaccination: Association with FGFR3 Autoantibodies and Improvement during Intravenous Immunoglobulin Treatment Mastropaolo M et al Case Reports Neurology 2023
- Neuropathic symptoms with SARS-CoV-2 vaccination Nath A et al medRxiv. Preprint. 2022 May 17.
- Small Fiber Neuropathy Associated With the Moderna SARS-CoV-2 Vaccine Khokhar F et al Cureus July 2022
- Post COVID-19 vaccine small fiber neuropathy. Tandan R Muscle Nerve. 2021
- Small fiber neuropathy with normal intra-epidermal nerve fiber density but reduced sweat gland density after third BNT162b2 shot Fiinister
 J Arch Clin Case 2023
- Severity of neurological long-COVID symptoms correlates with increased level of autoantibodies targeting vasoregulatory and autonomic nervous system receptors Seibert F et al Autoimmunity Reviews Sept 2023
- Serotonin reduction in post-acute sequelae of viral infection Wong A et al Cell September 2023
- Neuropathic symptoms with SARS-CoV-2 vaccination Nath A et al medRxiv. Preprint. 2022 May 17.
- Small Fiber Neuropathy after COVID-19: A Key to Long COVID McAlpine L et al medRxiV 2023
- Small fiber neuropathy in the cornea of Covid-19 patients associated with the generation of ocular surface disease Barros A et al Ocul Surf. 2022

References Alpha Synuclein and EDS and Musculoskeletal Problems

- Cutaneous alpha-synuclein deposition in postural tachycardia patients Levine T et al Ann Clinical Translational Neurology
- A case series of cutaneous phosphorylated α -synuclein in Long-COVID POTS Miglis M et al Clinical Autonomic Research 2022
- Cutaneous alpha-synuclein deposition in postural tachycardia patients Levine T et al Ann Clinical Translational Neurology
- Autonomic Dysfunction in α -Synucleinopathies Mendoza Velasquez J et al Front Neurology Autonomic Science 2019
- Long COVID and the Diagnosis of Underlying Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders Logarbo B et al PM&R Dec 2023
- People with Long COVID and ongoing brain fog, joint, muscle and nerve pain, are more likely to have Generalized Joint Hypermobility Hakim A et al Hypermobility Syndrome Association 2022
- New Clinical Phenotype of the Post-Covid Syndrome: Fibromyalgia and Joint Hypermobility Condition Gavrilova M et al Pathophysiology 2022
- Musculoskeletal complications in long COVID-19: A systematic review Swarnaker R et al World J Virology 2022

POTS References

- Autoimmunity in Long Covid and POTS Fatema-Zahra El-Rhermoul et al Oxford Open Immunology, 2023
- Vagus nerve inflammation contributes to dysautonomia in COVID-19 Woo M et al Acta Neuropathology 2023
- Serotonin reduction in post-acute sequelae of viral infection Wong A Cell 2023
- Platelet Delta Granule and Serotonin Concentrations Are Decreased in Patients with Postural Orthostatic Tachycardia Syndrome Rinker L et al Blood 2009
- Functional autoantibodies against G-protein coupled receptors in patients with persistent long-COVID-19 symptoms. Wallukat G et al J Transl Autoimmun 2021
- Postural orthostatic tachycardia syndrome is associated with elevated G-protein coupled receptor autoantibodies. Gunning WT et al J Am Heart Assoc 2019
- The Pathophysiology of Long COVID throughout the Renin-Angiotensin System Khazaii S et al Molecules 2022

POTS References

- Tillman, T.S et al. SARS-CoV-2 Spike Protein Downregulates Cell Surface alpha7nAChR through a Helical Motif in the Spike Neck. ACS Chem. Neurosci.2023
- Multisystem Inflammatory Syndrome in Children and Long COVID: The SARS-CoV-2 Viral Superantigen Hypothesis Rivas M Frontiers of Immunology July 2022
- Nicotinic Acetylcholine Receptor Involvement in Inflammatory Bowel Disease and Interactions with Gut Microbiota Ruzafa L et al Int J Environ Res Public Health. 2021 Feb
- A potential interaction between the SARS-CoV-2 spike protein and nicotinic acetylcholine receptors Sofia A et al Biophys J Mar 2021
- COVID-19 Vaccination and Late-Onset Myasthenia Gravis: A New Case Report and Review of the Literature Virgilo E et al Environmental Research and Public Health Jan 2023
- Mast Cell Activation Disorder and Postural Orthostatic Tachycardia Syndrome: A Clinical Association Kohono R et al Journal of American Heart Association 2021
- Mast cell disorders are associated with decreased cerebral blood flow and small fiber neuropathy. Novak P et al Ann Allergy, Asthma Immunol. 2022
- Mast Cells in the Autonomic Nervous System and Potential Role in Disorders with Dysautonomia and Neuroinflammation Theoharides T et al Annals of Allergy and Immunology Nov 2023

Oxytocin References

- Clinical and neural effects of six-week administration of oxytocin on core symptoms of autism Watanabe T et al . Brain. 2015
- Oxytocin in brain health and disease: how can it exert such pleiotropic neuromodulator effects? Talpo F et al Front of Mol Science 2023
- The oxytocin receptor represents a key hub in the GPCR heteroreceptor network: potential relevance for brain and behavior Borroto-Escuela D Frontier Molecular Neuroscience 2021
- Oxytocin in Huntington's disease and the spectrum of amyotrophic lateral sclerosis-frontotemporal dementia Berg S et al Mol Neuroscience 2021
- Hippocampal volume modulates salivary oxytocin level increases after intranasal oxytocin administration Rierm M et al Psychoneuroendocrinology 2019
- Oxytocin attenuates microglial activation and restores social and non-social memory in APP/PS1 Alzheimer model mice Selles M et al Science 2023
- Oxytocin alleviates cognitive and memory impairments by decreasing hippocampal microglial activation and synaptic defects via OXTR/ERK/STAT3 pathway in a mouse model of sepsis-associated encephalopathy. Jiang G et al Brain Behavior and Immunity 2023
- Xu D, Li Q, Zhuang Q, et al., Oro-mucosal administration of oxytocin using medicated lollipops alters social attention, similar to intranasal and lingual routes: Implications for therapeutic use. Front Neurosci. 2022 Oct

Oxytocin References

- Oxytocin ameliorates ischemia/reperfusion-induced injury by inhibiting mast cell degranulation and inflammation in the rat heart Xiong W et al Biomedicine & Pharmacotherapy 2019
- Nasal oxytocin for the treatment of psychiatric disorders and pain: achieving meaningful brain concentrations. Yeomens DC et al Transl Psychiatry. 2021
- Intranasal Oxytocin Attenuates Cognitive Impairment, β-Amyloid Burden and Tau Deposition in Female Rats with Alzheimer's Disease: Interplay of ERK1/2/GSK3β/Caspase-3 El-Ganainy S et al Neurochem Research 2022
- Tinnitus Treatment with Oxytocin: A Pilot Study Acevedo A Frontiers Neurology 2017
- Oxytocin promotes epicardial cell activation and heart regeneration after cardiac injury. Lewis Israeli YR et al Front Cell Dev Biol. 2022;
- Oxytocin and vasopressin in the hippocampus. Ziagrean AM et al Vitam Horm. 2022.
- Clinical and neural effects of six-week administration of oxytocin on core symptoms of autism Watanabe T et al . Brain. 2015

Oxytocin References

- Effects of route of administration on oxytocin-induced changes in regional cerebral blood flow in humans Martins D et al Nature Communications 2020
- The Role of Oxytocin in Cardiovascular Protection. Jankowski M et al Front Psychol. 2020
- Oxytocin increases autonomic cardiac control: moderation by loneliness Norman G et al Bio Psycho 2011
- The vagus nerve mediates the suppressing effects of peripherally administered oxytocin on methamphetamine self-administration and seeking in rats Everett N et al Neuropsychopharmacology 2021
- <u>https://www.suzannegazdamd.com/blog/the-brain-in-loveforever-and-always</u>

IVIG References

- Small Fiber Neuropathy Triggered by COVID-19 Vaccination: Association with FGFR3 Autoantibodies and Improvement during Intravenous Immunoglobulin Treatment Mastropaolo M et al Case Reports Neurology 2023
- IVIg for small fiber neuropathy with autoantibodies TS-HDS and FGFR3. Gibbons C et al Clinicaltrials.gov. 2021
- Small Fiber Neuropathy after COVID-19: A Key to Long COVID McAlpine L et al medRxiV 2023
- Post COVID-19 vaccine small fiber neuropathy. Waheed W et al Muscle and Nerve. 2021
- Long-term high-dose immunoglobulin successfully treats Long COVID patients with pulmonary, neurologic, and cardiologic symptoms Thompsen JS et al Front Immunology Feb 2023
- Intravenous immunoglobulins in the treatment of post-COVID: A case–control study Nov 2022
- Intravenous immunoglobulin (IVIG) promotes brain repair and improves cognitive outcomes after traumatic brain injury in a FcγRIIB receptor-dependent manner Willis E Nature 2023
- Intravenous immunoglobulin suppresses the polarization of both classically and alternatively activated macrophages. Hum Vaccin Immunother. 2020

IVIG References

- Efficacy of intravenous immunoglobulin (IVIg) on COVID-19-related neurological disorders over the last 2 years: an up-to-date narrative review. Manganotti P, et al Front Neurosci. 2023
- Treatment of Cognitive Deficits and Behavioral Symptoms Following COVID-19-Associated Autoimmune Encephalitis With Intravenous Immunoglobulin: A Case Report and Review of the Literature Naeem S et al Cureus 2023
- Update on intravenous immunoglobulin in neurology: modulating neuro-autoimmunity, evolving factors on efficacy and dosing and challenges on stopping chronic IVIG therapy. Dalakas MC. Neurotherapeutics 2021
- Small Fiber Neuropathy after COVID-19: A Key to Long COVID McAlpine L et al medRxiV 2023
- Case Series: Post-COVID Small Fiber Neuropathy McAlpine BVS 2022
- Intravenous Immunoglobulin Therapy in Patients With Painful Idiopathic Small Fiber Neuropathy Geerts M Neurology 2021
- Large Review Suggests IVIG is Effective for Neurological Diseases Following COVID-19 Infection Pharmacy Times 2023
- Neuralgic Amyotrophy After COVID-19 Vaccination in an Adolescent: Successful Intravenous Immunoglobulin Treatment Fukahori K et al Pediatric Neurology 2022
- https://www.suzannegazdamd.com/blog/update-even-more-results-for-ivig-in-treating-small-fiber-neuropathy

Muscle/Ligament References

- Creatine Supplementation and Brain Health Roschel H et al Nutrients 2021
- Effects of six-month creatine supplementation on patient- and clinician-reported outcomes, and tissue creatine levels in patients with post-COVID-19 fatigue syndrome Slankamenac J et al Food Science and Nutrition Sept 2023
- L-Carnitine Tartrate Downregulates the ACE2 Receptor and Limits SARS-CoV-2 Infection Bellamine A et al Nutrients 2021
- Can l-carnitine reduce post-COVID-19 fatigue? Vazari-Harmai R et al Ann Med Surg 2022 Jan
- I-Carnitine Supplementation in Recovery after Exercise Fielding R et al Nutrients 2018
- L-Carnitine Tartrate Supplementation for 5 Weeks Improves Exercise Recovery in Men and Women: A Randomized, Double-Blind, Placebo-Controlled Trial Stefan M et al Nutrients 2021
- Clinical Study on the Efficacy and Safety of Arginine Administered Orally in Association with Other Active Ingredients for the Prevention and Treatment of Sarcopenia in Patients with COVID-19-Related Pneumonia, Hospitalized in a Sub-Intensive Care Unit Bologna C et al Healthcare 2022
- Pharmacological targeting of age-related changes in skeletal muscle tissue Handschin C et al Pharmacological Research 2020
- Post-COVID-19 acute sarcopenia: physiopathology and management Veronese N et al Aging Clin Exp Res. 2021;
- Blood Flow Restriction Therapy for Stimulating Skeletal Muscle Growth: Practical Considerations for Maximizing Recovery in Clinical Rehabilitation Settings Bradley L Techniques in Orthopedics June 2018
- Time-restricted ketogenic diet in amyotrophic lateral sclerosis: a case study Phillips M et al Front Neurology 2024
- Nutritional research may be useful in treating tendon injuries Curtis L Nutrients 2016
- SARS-CoV-2 Spike Protein Induces Hemagglutination: Implications for COVID-19 Morbidities and Therapeutics and for Vaccine Adverse Effects Boschi C et al Int J of Molecular Science 2022 (supports abnormal ZETA potential)

References on PEM findings in Long Covid

- Myopathy as a cause of fatigue in long-term post-COVID-19 symptoms: Evidence of skeletal muscle histopathology Hejbol EK et al European J of Neurology 2022
- Myopathic changes in patients with long-term fatigue after COVID-19 Agergaard J Clinical Neurophysiology 2021
- Maximal oxidative capacity during exercise is associated with muscle power output in patients with long coronavirus disease 2019 (COVID-19) syndrome. A moderation analysis Ramirez-Velez et al Clinical Nutrition ESPEN 2023
- Post-COVID exercise intolerance is associated with capillary alterations and immune dysregulations in skeletal muscles Ashman T et al Acta Neuropathologica Communications 2023
- Differential Cardiopulmonary Hemodynamic Phenotypes in PASC Related Exercise Intolerance Kahn P et al ERJ Open Research 2023
- Yamamoto K, Takeshita H, Rakugi H. ACE2, angiotensin 1-7 and skeletal muscle: review in the era of COVID-19. Clin Sci (Lond). 2020;
- Functional characterization of the ACE2 orthologues in Drosophila provides insights into the neuromuscular complications of COVID-19 Herrera P et al BBA Molecular Basis of Disease 2021
- Development of ACE2 autoantibodies after SARS-CoV-2 infection Arthur J et al PLOS One 2021

Montelukast/L Theanine References

- Exploring the neuroprotective effects of montelukast on brain inflammation and metabolism in a rat model of quinolinic acid-induced striatal neurotoxicity Mazzacco M et al J of inflammation 2023
- Leukotriene receptor antagonist use and cognitive decline in normal cognition, mild cognitive impairment, and Alzheimer's dementia Xiong L et al Alzheimer's Research & Therapy 2021
- The neuropharmacology of L-theanine(N-ethyl-L-glutamine): a possible neuroprotective and cognitive enhancing agent. Nathan P et al J Herb Pharmacother. 2006
- I-Theanine, an amino acid in green tea, attenuates beta-amyloid-induced cognitive dysfunction and neurotoxicity: reduction in oxidative damage and inactivation of ERK/p38 kinase and NF-kappaB pathways. Kim T et al Free Radic Biol Med. 2009
- Protective effect of the green tea component, L-theanine on environmental toxins-induced neuronal cell death. Cho S et al Neurotoxicology. 2008
- L-Theanine reduces psychological and physiological stress responses. Kimura K et al Biol Psychol. 2007

Vit K 2/ALCAR References

- Vitamin K2 Modulates Mitochondrial Dysfunction Induced by 6-Hydroxydopamine in SH-SY5Y Cells via Mitochondrial Quality-Control Loop Tang H et al Nutrients 2022
- Vitamin K2 Holds Promise for Alzheimer's Prevention and Treatment Popescu A et al Nutrients 2021
- Association of Vitamin K Insufficiency with Cognitive Dysfunction in Community-Dwelling Older Adults Azuma K et al Frontiers Nutrition 2021
- Vitamin K2 (Menaquinone-7) Reverses Age-Related Structural and Cognitive Deterioration in Naturally Aging Rats Elkattawy H et al Antioxidants 2021
- Acetyl-L-carnitine permeability across the blood-brain barrier and involvement of carnitine transporter OCTN2 Inano A et al pharm Drug Dispos 2003
- Acetyl-l-carnitine for dementia Hudson S et al Cochrane Database Systemic Review 2003
- Acylcarnitines: role in brain. Jones LL et al Progress in lipid research 49, 2010
- Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update Pennisi M et al Nutrients 2020

PQQ, Fisetin and ALA

- Pyrroloquinoline quinone inhibits the fibrillation of amyloid proteins. Kim J et al Prion. 2010.
- Protective effect of pyrroloquinoline quinone against Abeta-induced neurotoxicity in human neuroblastoma SH-SY5Y cells. Zhang JJ et al Neurosci Lett. 2009
- Pyrroloquinoline quinine protects rat brain cortex against acute glutamate-induced neurotoxicity. Zhang Q et al Neurochem Res. 2013
- Stimulation of nerve growth factor production by pyrroloquinoline quinone and its derivatives in vitro and in vivo. Yamaguchi Y et al Biosci Biotechnol Biochem. 1993
- "Alpha-lipoic acid as a new treatment option for Alzheimer's disease—a 48 month follow-up analysis." Munch G et al Journal of Neural Transmission. Supplementum. 2007
- "Alpha-Lipoic acid protects against reperfusion injury following cerebral ischemia in rats." Ravindranath V. et al Brain Research. 1996 Apr 22;717
- Preventing and Treating Neurological Disorders with the Flavonol Fisetin Maher P Brain Plasticity, 2020

Luteolin References

- Long-COVID syndrome-associated brain fog and chemo fog: Luteolin to the rescue Theoharides T et al Biofactors 2021
- Protection against Alzheimer's disease by luteolin: Role of brain glucose regulation, antiinflammatory activity, and the gut microbiota-liver-brain axis Daily J et al Biofactors Dec 2020
- Luteolin Supplements: All the Glitters is Not Gold Theoharides T Editorial 2020
- Brain "fog," inflammation and obesity: key aspects of neuropsychiatric disorders improved by luteolin Theoharides T Frontiers Neuroscience 2015
- Luteolin as a therapeutic option for multiple sclerosis Theoharides T J Neuroinflammation 2009
- Luteolin inhibits spike protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) binding to angiotensin-converting enzyme 2 Zhu J et al Phytotherapy Research May 2023

- Six-month RCT looking at EPA and DHA in patients with AD: Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial Freund-Levi V et al Archives Neurology 2006
- Effect of omega-3 fatty acids and fish oil supplementation on multiple sclerosis: a systematic review 2019 Alaamar W et al An International Journal on Nutrition, Diet and Nervous System 2021
- CDP-choline: pharmacological and clinical review Secades J et al Methods Find Exp Clin Pharmacol 1995
- Citicoline (CDP-choline) increases Sirtuin1 expression concomitant to neuroprotection in experimental stroke Hurtado O et al J Neurochem.(2013 Apr 18)
- Probenecid, an Old Drug with Potential New Uses for Central Nervous System Disorders and Neuroinflammation Garcia-Rodriquez C et al Biomedicine 2023
- N-Acetylcysteine and Probenecid Adjuvant Therapy for Traumatic Brain Injury Clark R et al Neurotherapeutics 2023
- Effect of multivitamin-mineral supplementation versus placebo on cognitive function: results from the clinic subcohort of the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial and meta-analysis of 3 cognitive studies within COSMOS Viyas C et al American J of Nutrition Jan 2024